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EXECUTIVE SUMMARY
This report, required by Chapter 258 of the Acts of 2014, 
An act to increase opportunities for long-term substance abuse 
recovery, presents new information and data on the state of 
the opioid epidemic in Massachusetts, its disproportionate 
impact on certain residents, communities, and hospitals, 
and the statewide availability of opioid use disorder treat-
ment. The report further identifies strategies to enhance 
access to treatment and promote the development of 
innovative care delivery and payment models that focus 
on at-risk populations. 
This report is informed by, and is presented as a comple-
ment to, the extensive and far-reaching efforts of many 
in the Commonwealth to address the opioid epidemic, 
including Governor Baker’s Opioid Addiction Working 
Group (Appendix 1) and recent enactment of landmark, 
nation-leading laws, including: 
• Chapter 55 of the Acts of 2016: An act requiring cer-
tain reports for opiate overdoses, which directs the De-
partment of Public Health (DPH) to assess factors 
contributing to increasing overdose rates using a 
multitude of datasets; and 
• Chapter 52 of the Acts of 2016: An act relative to sub-
stance use, treatment, education and prevention, which 
in part, directs the Health Policy Commission (HPC) 
to take further steps to address the impact of the 
opioid epidemic on the health care system.
The HPC is an independent state agency established by 
Chapter 224 of the Acts of 2012, An act improving the 
quality of health care and reducing costs through increased 
transparency, efficiency and innovation. The mission of the 
HPC is to monitor the reform of the health care deliv-
ery and payment systems in Massachusetts and develop 
innovative health policy to reduce overall cost growth 
while improving the quality of patient care. Critical to 
this work is the integration of behavioral health into the 
health care system (both at the primary care and acute 
levels), which the HPC promotes through its research 
agenda, certification programs, investments, and pro-
motion of alternative payment models that support care 
delivery reform. 
The opioid epidemic in Massachusetts has struck com-
munities across the state at an increasingly rapid pace, 
causing widespread morbidity and mortality, reduced 
productivity, and increased poverty and incarceration 
rates. A multitude of public and private entities are allo-
cating tremendous resources to combat this public health 
threat. No one solution exists: preventing and treating 
opioid use disorder requires a multi-pronged approach, 
encompassing coordinated efforts among local commu-
nities, courtrooms, police and fire departments, schools, 
and the health care system. 
This report focuses on the epidemic's impact on the health 
care system, and is being released concurrently with the 
Department of Public Health's (DPH) report on factors 
contributing to both fatal and non-fatal overdoses. Togeth-
er, these reports provide the state with in depth assessments 
of opioid use disorder and opioid misuse that results in 
any hospital utilization, as well as that which results in 
overdose, at which point patients are at greatest risk. 
While this report focuses on the impact of opioid use 
disorder on the health care system only, it does not dismiss 
the tremendous importance of other necessary prongs of 
intervention. Rather, the HPC seeks to add value to the 
wide-ranging activities already in motion by identifying 
areas where the HPC’s specific role to promote health 
care system transparency, accountability, and efficiency 
can be leveraged as part of the Commonwealth’s efforts 
to combat opioid use disorder. 
DATA FINDINGS
In order to better understand the impact of the opioid 
epidemic on the healthcare system, the HPC analyzed:
• the rate of opioid-related hospital utilization across 
the state (including both emergency department (ED) 
and inpatient discharges); 
• the total volume of opioid-related discharges by hos-
pital (including both ED and inpatient discharges); 
• the total volume of neonatal abstinence syndrome 
(NAS) discharges by hospital; and
• the availability of outpatient pharmacologic treatment 
for opioid use disorder. 
The major findings include:
• Between 2007 and 2014, all opioid-related hospital 
discharges increased by 84%; those coded as hero-
in-related increased by 201%.
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• In 2014, residents living in the Berkshires, Fall River, 
Metro South, New Bedford and East Merrimack re-
gions had the highest rates of opioid-related hospital 
discharges.i 
• In 2014, Boston Medical Center, Good Samaritan 
Medical Center, and Mercy Medical Center had the 
highest volume of opioid-related hospital discharges 
across all hospitals in the Commonwealth.
• In 2014, MassHealth paid for 42% of opioid-relat-
ed discharges and Medicare covered an additional 
24%. Opioid-related hospital discharges were highest 
among males, young adults, and individuals from 
low-income communities.
• Opioid use disorder can be effectively treated with 
pharmacologic intervention combined with evi-
dence-based behavioral therapy.1 In the Common-
wealth, these providers are heavily concentrated in 
the most densely populated areas of the state and 
the majority are clustered in eastern Massachusetts. 
• Many patients who had an opioid-related hospital 
discharge in 2014 live more than five miles from the 
nearest pharmacologic treatment provider, particularly 
those residing in the least densely populated areas 
such as the Berkshires and the upper North Shore.
POLICY RECOMMENDATIONS
In light of these findings, as well as the HPC’s experience 
with other behavioral health-related policy work and in-
vestments, this report makes targeted recommendations 
for the Commonwealth to: 
1 support ongoing data collection and analysis of the 
opioid epidemic; 
2 integrate pharmacologic treatment interventions into 
health care systems to improve access to opioid use 
disorder treatment and wrap-around supports, par-
ticularly in the primary care and ED settings; 
3 promote use of broad-based, multi-stakeholder co-
alitions between community hospitals, outpatient 
i The 66 Hospital Service Areas (HSAs) in Massachusetts defined by 
the Dartmouth Atlas were merged into 15 larger HPC geographic 
regions. HPC’s 15 geographic regions were identified according 
to where residents of those regions traveled for inpatient care. 
For more details on how HPC identified its geographic regions, 
please see http://www.mass.gov/anf/docs/hpc/2013-cost-trends-re-
port-technical-appendix-b3-regions-of-massachusetts.pdf
providers, patients and their families, and other key 
stakeholders to address the epidemic locally; and 
4 invest in and promote innovative care delivery and 
payment models that focus on the most at-risk 
patients. 
The report further identifies ways in which the HPC cur-
rently supports or plans to support innovative solutions 
in the health care system to manage patients suffering 
from opioid use disorder. 
Policy recommendations are informed by the analyses 
generated for this report, extensive stakeholder input, 
and lessons learned from ongoing HPC activities. The 
recommendations are strategically aligned with the myriad 
ongoing efforts across the Commonwealth. 
Recommendation 1: The Commonwealth should 
systematically track the impact of the opioid epi-
demic on the health care system and the availability 
of evidence-based pharmacologic treatment.
Recommendation 2: The Commonwealth should 
increase access to and effectiveness of evi-
dence-based opioid use disorder treatment by inte-
grating pharmacologic interventions into systems 
of care.
a) Payers should support the integration of opioid use 
disorder treatment into primary care. 
b) Payers should contract with adequate networks of 
community-based behavioral health providers to im-
prove access to community-based care.
c) Payers should support initiation of opioid use disorder 
treatment in acute care settings in coordination with 
accountable, integrated systems that allow for timely 
access to follow-up care.
d) Payers should facilitate the collaboration between 
providers of different levels of care to minimize loss 
to follow-up during transitions between settings.
Recommendation 3: The Commonwealth should 
support coordinated, multi-stakeholder coalitions 
to address the impact of the opioid epidemic locally.
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Recommendation 4: The Commonwealth should test, 
evaluate, and scale innovative care models for pre-
venting and treating opioid use disorder and related 
conditions, including through:
a) Initiation of buprenorphine treatment in the ED;
b) Innovative neonatal abstinence syndrome (NAS) 
treatment models; and
c) Telemedicine.
THE STATE OF THE OPIOID 
EPIDEMIC IN MASSACHUSETTS 
As rates of opioid-related hospital discharges and deaths 
continue to climb across the Commonwealth, public and 
private medical and behavioral health service providers 
struggle to keep pace with the growing demand for treat-
ment services and prevention strategies.2 To date, only 
opioid-related mortality has been consistently measured by 
the Commonwealth. Morbidity-related statistics by city/
town, analogous to the mortality statistics published by 
the Department of Public Health (DPH) could be used 
to better identify areas of the state in which patients have 
particularly limited access to timely treatment. This report 
adds the following analyses to the statewide effort to track 
and address the growing opioid use disorder epidemic: 
• the rate of opioid-related hospital utilization across 
the state (including both emergency department (ED) 
discharges and inpatient discharges);
• the total volume of opioid-related hospital discharges 
by hospital;
• the total volume of neonatal abstinence syndrome 
(NAS), a syndrome affecting infants exposed to opi-
oids in utero, discharges by hospital; and
• the availability of outpatient pharmacologic treatment 
for opioid use disorder. 
OPIOID-RELATED MORTALITY 
The prevalence of opioid use disorder has reached epidemic 
status worldwide.3 This trend is particularly concerning 
in the United States, where approximately 25% of all 
worldwide opioid-related deaths occur.4 Locally, the pro-
portion of opioid-related overdoses is also increasing 
significantly: as of August 2016, there were 1,531 con-
firmed unintentional and/or undetermined opioid-related 
deaths in Massachusetts in 2015, a 150% increase over 
2011 and a 18% increase over 2014 (see Figure 1).5
Heroin and fentanyl are causing the greatest number of 
fatal overdoses; in 2016, nearly 70% of opioid related 
mortality was caused by fentanyl, a stark increase from 
2014, reflective of the quickly changing nature of the 
epidemic (see Figure 2).
Figure 1: Opioid-relateddeaths,unintentional/undeter-
mined, Massachusetts: 2000-20156
Source: Massachusetts Department of Public Health, August 2016
Note: Suicides are excluded from this analysis.
200
400
600
800
1000
1200
1400
1600
2
0
1
5
2
0
1
4
2
0
1
3
2
0
1
2
2
0
1
1
2
0
1
0
2
0
0
9
2
0
0
8
2
0
0
7
2
0
0
6
2
0
0
5
2
0
0
4
2
0
0
3
2
0
0
2
2
0
0
1
2
0
0
0
335
486 505
587
494
554
635 617 587 610
532
613
698
918
1659
1294
1350
1531
Conrmed Estimated
Year and Quarter
P
e
rc
e
n
t
2014
1 2 3 4 1 2 3 4 1
2015 2016
80
70
60
50
40
30
20
10
Prescription
Cocaine
Benzodiazepine
Likely Heroin
Fentanyl
Year and Quarter
P
e
rc
e
n
t
2014
1 2 3 4 1 2 3 4 1
2015 2016
80
70
60
50
40
30
20
10
Prescription
Cocaine
Benzodiazepine
Likely Heroin
Fentanyl
Year and Quarter
P
e
rc
e
n
t
2014
1 2 3 4 1 2 3 4 1
2015 2016
80
70
60
50
40
30
20
10
Prescription
Cocaine
Benzodiazepine
Likely Heroin
Fentanyl
Figure 2: Percentofopioid-relateddeathswithspecific
drugpresent,Massachusetts:2014-2016
Source: Massachusetts Department of Public Health, August 2016
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Between 2010 and 2014, the rate of opioid-related drug 
overdose deaths in Massachusetts increased more rapidly 
than the national average, even as the state increased 
availability of treatment and overdose prevention services 
(see Figure 3).ii 
Figure 3: Opioid-related drug overdose deaths per 100,000, 
1999-2014,MassachusettsandUS
Source:MultipleCauseofDeathdata(1999-2014)areproducedbytheDivision
ofVitalStatistics,NationalCenterforHealthStatistics(NCHS),Centersfor
DiseaseControlandPrevention(CDC),UnitedStatesDepartmentofHealth
andHumanServices(USDHHS)iii
Note:Massachusettsnumbersarenotincludedintheage-adjustedweighted
national average. 2015 data are not yet available from the CDC.
RatesbasedonNCHSdatadifferfromDPHpublishedratesbecauseDPH
usesastatisticalfilethatisclosedlaterthantheNCHSfileandincludesmore
casesthathaveafinalcauseofdeathassigned.
OPIOID-RELATED HOSPITAL DISCHARGES 
To further understand the extent of the impact of the 
epidemic beyond mortality, the HPC examined the toll 
of the epidemic on use of the health care system. The 
HPC found that between 2007 and 2014, heroin-related 
hospital discharges increased by 201% and opioid-related 
ii In response to this trend, a number of key stakeholders in the 
Commonwealth enacted changes to prescribing and other clinical 
practices. As of January 2011, prescribers were required to complete 
education units on pain management, SUD identification, and 
counseling patients on the risks of addiction. In July 2013, DPH 
was directed to report on the number of schedule II prescriptions 
prescribed each month. In March 2014, then Governor Deval 
Patrick declared a public health emergency in response to the 
observed growth in opioid use disorder and overdose. Upon taking 
office in 2015, Governor Baker established the Opioid Addiction 
Working Group, which released 65 targeted recommendations 
in June 2015. For more information on these recommendations, 
please refer to Appendix 1.
iii Drug overdose deaths (IDC-10 codes X40–44, X60–64, X85, 
Y10–Y14) that were opioid-related (ICD-10 codes T40.0, T40.1, 
T40.2, T40.3, T40.4, T40.6) between 1999 and 2014, were 
used in this analysis. CDC provided age-adjusted death rates per 
100,000 for each state; for comparison purposes, the national 
age-adjusted death rate was adjusted for population.
hospital discharges increased by 84% (see Figure 4).iv 
This reflects that misuse of prescription opioids continues 
to drive a significant and growing portion of opioid-related 
hospital utilization, whereas heroin and fentanyl drive 
the largest proportion of opioid-related deaths as described 
above.
iv See data note. 
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Figure 4: Opioid-related hospital discharges, Massachu-
setts,2007-2014
Rate of Change of Opioid-Related Hospital Discharges
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database, 
Outpatient Observation Database, and Emergency Department Database, 
2007-2014
Note: Hospital discharges include ED discharges, inpatient discharges, and 
observation stay discharges. The remainder of analyses do not include ob-
servationstaydischarges.Dischargeswithbotha“heroin-related”and“other
opioid”dischargecodearecountedonlyonceinthe“allopioidscategory”,
aswellasinbothofthesub-categories.Forexample,apatientcodedwith
aheroinoverdoseandanon-heroinoverdosewouldbecountedonceinthe
“heroin-related”categoryandonceinthe“otheropioid”category.However,
if a discharge had multiple diagnoses for the same sub-category (e.g., both 
aheroinoverdoseandheroinpoisoning),thedischargewouldbecounted
only once in the heroin-related sub-category. 
*ThisanalysisisbasedonICD-9codesandincludesdischargeswithanopi-
oid-relatedprimaryorsecondarydiagnosis.Aswithallanalysesdependent
onICD-9codes,providercodingmaynotalwaysfullyaccuratelyreflectthe
patient’sclinicalcondition.Inparticular,heroin-relatedcodesareconsidered
specific,butnotnecessarilysensitive.Forexample,somehospitalsmay
onlyuseheroin-relatedcodesforcasesofpoisoning/overdose.Asresult,
someheroinabuse/dependenceislikelycapturedinthe“otheropioids”
category. Furthermore,  some non-heroin opioid cases are likely captured 
inthe“heroin-related”category.
Years Heroin-related Other opioids
2007-2008 6% 6%
2008-2009 11% 15%
2009-2010 -29% 6%
2010-2011 52% 6%
2011-2012 23% 13%
2012-2013 35% 8%
2013-2014 43% 5%
201% 
increase in 
heroin-related 
hospital 
discharges 
between2007
and2014
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Opioid-Related Hospital Discharges: Impact 
on Communities
The opioid epidemic has had a particularly profound im-
pact in discrete communities and on specific populations 
in the Commonwealth. Although there are pockets of 
high rates of opioid-related use of the health care system 
throughout the state, residents living in the Berkshires, Fall 
River, Metro South, New Bedford, and East Merrimack 
regions are disproportionately affected. Hospital utiliza-
tion data calculated using patient zip codes suggest that 
there may be an especially high need for increased access 
to treatment in those regions (see Figure 5).
Figure 5: Opioid-related hospital discharges by HPC region, 
2014v, vi
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges include both ED and inpatient discharges, but 
not observation stays. 
To drill down further than the regional level, the HPC 
mapped opioid-related hospital utilization by patient zip 
code (see Figure 6) and by city and town, creating an 
analog to DPH’s opioid-related mortality statistics (see 
Appendix 4). The data also is broken down by gateway 
cities.vii As shown in Appendix 5, the zip codes in which 
v This and subsequent figures show the community impact as the 
number of discharges per 100,000 residents. The 66 Hospital 
Service Areas (HSAs) in Massachusetts defined by the Dartmouth 
Atlas were merged into 15 larger HPC geographic regions. HPC’s 
15 geographic regions were identified according to where residents 
of those regions traveled for inpatient care. For more details on 
how HPC identified its geographic regions, please see http://www.
mass.gov/anf/docs/hpc/2013-cost-trends-report-technical-appen-
dix-b3-regions-of-massachusetts.pdf
vi While rates of opioid-related hospital discharges are correlated 
with overall hospital use, there is much greater regional variation 
in opioid-related hospital discharges than there is in rates of overall 
hospital use (3 to 1 versus 2 to 1, respectively). The rate of opi-
oid-related hospital discharges as a percent of all discharges was 
highest in the Berkshires (2.3%) and lowest in Metro West (1.1%).
vii A gateway city is one with a population between 35,000 and 
250,000, median household income below the state average, and 
rate of attaining a bachelor’s degree is below the state average. 
M.G.L. c. 23A section 3A. http://www.mass.gov/hed/community/
planning/gateway-cities-and-program-information.html
residents are utilizing hospitals at the highest rates for 
opioid-related reasons are concentrated in the East Mer-
rimack, Metro Boston, Metro South, South Shore, and 
Central and Southeastern Massachusetts regions. 
Figure 6: Opioid-related hospital discharges by patient zip 
code,2014
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges include both ED discharges and inpatient dis-
charges.Tocontrolforextremevaluesinsmallcommunities,therateswere
truncated at the 98th percentile.
In addition to examining geographic distribution of pa-
tients, the HPC calculated the total volume of opioid-re-
lated discharges at each hospital in 2014 (see Figure 7). 
Hospitals across the Commonwealth treat large numbers 
of patients for opioid-related illness, but Boston Medi-
cal Center (Boston), Good Samaritan Medical Center 
(Brockton), and Mercy Medical Center (Springfield) had 
the highest volume of opioid-related hospital discharges. 
Appendix 6 includes each hospital by name as well as a 
“zoom in” of hospitals in Boston, given the density of 
hospitals in that area.
Figure 7: Opioid-related hospital discharges by hospital, 
2014
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges includes both ED discharges and inpatient dis-
charges, but not observation stays.
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Opioid-Related Hospital Discharges: Impact 
on Populations
In addition to regional variation of opioid-related hospital 
utilization across the Commonwealth, the opioid epidemic 
is disproportionately impacting specific populations. 
Males, young adults, and individuals from low-income 
communities were relatively more likely to have had an 
opioid-related inpatient discharge in 2014 (see Figure 8). 
Public payers bear the overwhelming burden of the fi-
nancial impact of the epidemic; in 2014, MassHealth, 
the Massachusetts Medicaid program, paid for 42% of 
all opioid-related inpatient discharges and Medicare cov-
ered an additional 24% (see Figure 9).
Opioid-Related Hospital Discharges: Impact 
on Exposed Infants
The growing opioid epidemic not only results in increased 
morbidity and mortality for adults and adolescents with 
addictions, but also affects infants exposed to opioids in 
utero.7 For example, about 60-80% of infants exposed to 
heroin or methadone in utero exhibit Neonatal Abstinence 
Syndrome (NAS) in the first few weeks of life.8 NAS is a 
clinical syndrome marked by low birth weight, respiratory 
distress, feeding difficulty, tremors, increased irritability 
and crying, diarrhea, and occasionally seizures.9,10,11 NAS 
is increasingly common; the number of affected infants 
nationally has increased 5-fold between 2000-2012.12 
While NAS is most commonly caused by in utero ex-
posure to opioids, the use of other substances during 
pregnancy can also cause NAS (e.g., selective serotonin 
reuptake inhibitors,13 benzodiazepines,14 inhalants,15 and 
methamphetamine16). Although the use of pharmacolog-
ic treatment (e.g., buprenorphine, methadone) to treat 
opioid use disorder during pregnancy can result in NAS, 
the American College of Obstetricians and Gynecologists 
(ACOG) recommends against tapering pregnant women 
off of pharmacologic treatment because of the associated 
risk of addiction relapse, which causes far greater harm 
to fetal and early child development.viii, 17 In fact, access 
viii While research demonstrates that abstinence during pregnancy 
does not have adverse effects on fetal development, such studies 
have not followed subjects after birth, when risk of relapse is 
highest. For more information, see: http://www.modernhealthcare.
com/article/20160331/NEWS/160339989?utm_source=mod-
ernhealthcare&utm_medium=email&utm_content=20160331-
NEWS-160339989&utm_campaign=dose
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Figure 9: Opioid-relatedinpatientdischargesbypayer,2014
Source:HPCAnalysis—CHIA,HospitalInpatientDischargeDatabase,2014
Note: The percentages indicate the principal payer for opioid-related inpatient 
dischargesin2014(n=17,756).ForthoseduallyeligibleforMedicaidandMedi-
care, Medicare is the principal p yer. Data includes only inpatient discharges, 
and does not include ED discharges or observation stays.
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to pharmacologic treatment during pregnancy reduces 
total health care expenditures for the woman and infant 
by approximately 30% in the first 6 months of life.18
Treatment of NAS has traditionally been resource-intensive 
and associated with extended length of stay (LOS), but 
emerging evidence suggests that it can be appropriately 
and cost-effectively treated in lower intensity and lower 
cost settings of care (e.g., by reducing use of pharmacologic 
intervention and implementing protocols that promote 
low-stimuli approaches such as breast feeding, swaddling, 
and skin-to-skin contact).19,20,21,22
NAS is particularly prevalent in Massachusetts; in 2009, 
the rate was approximately 3 times higher than the na-
tional average.23 At the national level, NAS prevalence 
increased 5-fold from 2000 to 2012 (from 1.2 infants per 
1000 live births to 5.8 infants per 1000 live births).24 The 
number of NAS discharges varies across the Common-
wealth; hospitals with highest rates are located in regions 
most impacted by the opioid epidemic. These hospitals 
include Charlton Memorial Hospital in Fall River, St. 
Luke’s Hospital in New Bedford, Cape Cod Hospital in 
Hyannis, Melrose-Wakefield Hospital in Melrose, and 
Berkshire Medical Center in Pittsfield (see Figure 10).
Not surprisingly, the distribution of NAS around the 
Commonwealth is reflective of the rate of opioid-related 
hospital utilization, but large NAS volume is also cor-
related with large total delivery volume, indicating that 
NAS discharges are not necessarily reflective of patient 
distribution (see Figure 11).
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Figure 10: DischargesofinfantswithNASbyhospital,
Massachusetts,2014
Source: HPC Analysis—CHIA, Hospital 
InpatientDischargeDatabase,2014
Note: This analysis only includes hos-
pitalswith12ormoreNASdischarges
using ICD-9-CM diagnosis code 779.5 
(drugwithdrawalsyndromeinanew-
born).DatadoesnotincludeEDdis-
charges or observation stays.
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Figure 11: NAS discharge volume by hospital compared 
tototaldeliveryvolume,2014
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Treatment of newborns with NAS is very expensive (see 
Figure 12). Costs are largely associated with LOS and 
time spent in higher intensity settings of care, such as 
the neonatal intensive care unit (NICU). The trend in 
prevalence of NAS in addition to the impact on healthcare 
spending makes NAS a particularly apt area for policy 
change and care delivery system improvement. 
Figure 12: AveragecostofinfantswithNAS,UnitedStates,
2009-201225
Source: Patrick et al., Journal of Perinatology, 2015
Note:TCOC=totalcostofcare.
AVAILABILITY OF PHARMACOLOGIC 
TREATMENT FOR OPIOID USE DISORDER 
Opioid use disorder can be effectively treated with phar-
macologic intervention combined with evidence-based 
behavioral therapy (e.g., cognitive behavioral therapy, 
contingency management, group counseling, and other 
forms of social and behavioral support).26,27 Some phar-
macologic treatments reduce opioid cravings (e.g., bu-
prenorphine, methadone); others have a blocking effect 
when combined with opioid ingestion, thereby deterring 
use (e.g., buprenorphine/naloxone, naltrexone). 
Pharmacologic treatment should be prescribed based on 
patients’ needs and preferences, to ensure care is patient 
centric. Addiction remains a stigmatized condition, cre-
ating intangible barriers to treatment. Patients report 
preferences for a supportive environment, engagement 
in their own care, and support and empathy from their 
providers.28 Patients may require assistance in obtaining 
insurance coverage, money for transportation, connec-
tion to childcare services, or other forms of assistance 
in mitigating relevant barriers to treatment. Providers’ 
awareness and consideration of patients’ preferences and 
competing priorities is therefore essential to ensuring 
treatment compliance. 
Pharmacologic treatments for opioid use disorder:
• Methadone is a daily opioid agonist treatment (e.g., a syn-
thetic drug that binds to opioid receptors, thereby controlling 
symptoms of withdrawal) that can only be administered 
by a federally licensed Opioid Treatment Program (OTP).29 
This requirement can hinder access due to travel and cost 
constraints; many patients are not able or willing to attend 
and/or pay for daily visits.30
• Buprenorphine is a long-acting partial opioid agonist that 
reduces opioid cravings by acting on the same brain recep-
tor targets that opiate analgesics (and heroin) target, without 
producing a “high” or dangerous side effects. Patients can 
receive a prescription to take the medication daily from any 
buprenorphine-waivered physician, rather than having to 
visit a clinic daily.31 In other words, buprenorphine can be 
prescribed in any clinical setting, including in primary care 
as long as the prescriber is waivered.
Both buprenorphine and methadone have street value, 
making precautions to prevent diversion critical.
• Extended-release naltrexone is an opioid antagonist 
delivered via a monthly injection. Naltrexone can be pre-
scribed by any health care provider licensed to prescribe 
medications and administered in any medical clinic or 
prescribed for purchase at the pharmacy.32 A full dose of 
naltrexone requires that the patient has not ingested or 
injected an opioid for at least 7-14 days. Such abstinence 
can be difficult for patients to achieve. Titration (determining 
the dose that reduces symptoms while avoiding possible 
side effects) is medically indicated to minimize adverse 
interactions between naltrexone and any remaining opioids 
in the patient’s system. 
Despite a strong evidence base, pharmacotherapy is un-
derutilized. Nationwide, fewer than 50% of adults and 
adolescents suffering from opioid use disorder received 
pharmacologic intervention in 2012.33 Some researchers 
estimate that access may be as low as 22% of patients with 
need.34 Increasing access to pharmacotherapy for opioid 
use disorder is a fundamental component to making 
the health care system more responsive to the treatment 
needs of patients. Consistent and reliable access to both 
pharmacologic intervention and evidence-based behav-
ioral therapy reduces rates of addiction, infectious disease 
transmission, and opioid-related hospital utilization.35 
Moreover, data on availability of pharmacologic treatment 
– as well as behavioral therapy – are incomplete, in terms 
of availability to providers, state agencies, and patients. 
For example, buprenorphine prescribers can opt out of 
being listed in SAMHSA’s publicly available database; 
naltrexone providers must opt in to being listed on a 
manufacturer’s website (Vivitrol Provider Locator); and 
methadone clinics, while publicly available by location, 
$20,000
$40,000
$60,000
$80,000
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vary in patient panel capacity. Ensuring the availability of 
comprehensive, up-to-date information on provider licen-
sure status, ability to accept new patients, and acceptance 
of public and private insurance is critical for increasing 
patients’ and providers’ ability to identify available treat-
ment options, as well as for allowing the state to better 
identify the largest gaps in availability. 
Despite imperfect data sources,ix the HPC conducted an 
analysis to identify the distribution of methadone, bu-
prenorphine, and naltrexone providers across Massachu-
setts, given the national data on the underutilization of 
pharmacotherapy. The HPC found that providers are 
heavily concentrated in the most densely populated areas 
of the state, namely Metro Boston and Springfield, and 
the vast majority are clustered in eastern Massachusetts 
(see Figure 13). Because 2 of the 3 forms of pharmaco-
therapy can be prescribed and/or administered in any 
clinical setting, the state has an opportunity to increase 
the number of providers who engage in pharmacologic 
treatment of opioid use disorder.x 
Many patients who had an opioid-related hospital dis-
charge in 2014 live more than five miles from the nearest 
ix Providers may choose to opt out of SAMHSA’s buprenorphine 
provider list. Additionally, some providers who appear on the 
list may not currently prescribe buprenorphine. There are also 
naltrexone providers who would not appear in Figure 11 if they 
did prescribe Vivitrol for 10 or more patients between July 2014 
and June 2015.
x The Office Based Opioid Treatment Program (OBOT) at Boston 
Medical Center (BMC) offers a Buprenorphine Hotline Pro-
gram that provides callers with referrals to treatment resources 
throughout the Commonwealth. For more information, please 
see: (http://www.mass.gov/eohhs/gov/departments/dph/programs/
substance-abuse/stop-pill-abuse/resources/massachusetts-helplines.
html)
pharmacologic treatment provider, particularly those re-
siding in the least densely populated areas (see Figure 14). 
For example: 
• Residents in the Berkshire region experienced the 
highest rate of opioid-related hospital discharges in 
2014 (68% higher rate of utilization than the state 
average) and would have to travel comparatively long 
distances to access pharmacotherapy (39% of patients 
would have to travel more than 5 miles to a buprenor-
phine provider, and 33% would have to travel more 
than 5 miles to a methadone clinic).
• Patients living in the Metro South region had a 42% 
higher rate of opioid-related hospital discharges in 
2014 than the average for state residents, and there 
are 46% fewer buprenorphine providers per capita 
in that region than the state average. 
• The Upper North Shore has the lowest availability of 
pharmacologic intervention, resulting in significant 
travel times for many patients (31% of patients would 
have to travel more than 5 miles to a buprenorphine 
provider).
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retrievedfromhttp://dpt2.samhsa.gov/treatment/directory.aspx
on11/20/2015)
Buprenorphine: Substance Abuse and Mental Health Services 
Administration. Buprenorphine Treatment Physician Locator (data 
retrievedfromhttp://www.samhsa.gov/medication-assisted-treat-
ment/physician-program-data/treatment-physician-locatoron
11/5/2015)
Naltrexone: Prescriber lists provided by Alkermes Pharmaceuticals 
(datareceivedon8/20/2015).Naltrexonelistincludeonlythose
whoprescribedVivitrolfor10ormorepatientsbetweenJuly
2014andJune2015
Figure 13: Pharmacotherapy providers for opioid use disorder, all types
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Assessing the Impact of Regulation on 
Availability of Pharmacotherapy Providers
To examine the current provider capacity, the HPC sur-
veyed buprenorphine prescribers. Buprenorphine prescrib-
ers are limited in the number of patients for whom they 
can provide pharmacologic treatment (at the time of this 
survey, physicians prescribing buprenorphine could not 
treat more than 100 patients at a time, a DEA restriction 
intended to reduce risk of diversion; providers can now 
treat up to 275 patients annually).xi The HPC survey 
was designed to assess the extent to which prescribers are 
operating to capacity, with respect to the patient cap, in 
primary care versus specialist settings.xii 
The survey revealed that 54% of respondents licensed to 
treat up to 100 patients were treating 80 or more indi-
viduals; 65% of these providers were addiction specialists. 
Primary care providers (PCPs), on the other hand, reported 
that the significant demands on time associated with the 
treatment (e.g., requirements around pill counts, urine 
toxicology screens)36 precluded them from approaching 
xi In July 2016, HHS issued a final rule increasing the patient cap 
from 100 to 275 patients. A bill pending in Congress would in-
crease the cap to 500. Either of these actions may increase access 
to licensed buprenorphine prescribers, although improved access 
likely also requires increasing the number of PCPs who prescribe 
buprenorphine. 42 CFR Part 8, 44576, Medication Assisted 
Treatment for Opioid Use Disorders Reporting Requirements, 
July 8 2016; S. 1455, Bill to provide access to medication-assisted 
therapy, and for other purposes, 114th Cong., 2d session. http://
www.markey.senate.gov/imo/media/doc/TREAT%20manag-
ers%20amendment.pdf.
xii This survey was sent to 150 buprenorphine providers, identified 
using SAMHSA’s Buprenorphine Physician Locator Tool. 48 
providers responded (32% of the sample).
the 100 patient cap. The majority of all respondents, re-
gardless of practice type, reported having a waitlist for new 
patients ranging from 2 days to 24 weeks.37 An increase 
in the number of patients a buprenorphine prescriber 
can treat at any given time may increase the number 
that addiction specialists can serve, but increasing the 
total volume of prescribers, particularly by integrating 
pharmacotherapy into primary care settings, is likely also 
necessary to approach adequate access to treatment.xiii, xiv
xiii Principles of the TREAT Act, which passed the HELP Committee 
in April 2016, were incorporated into Section 303 of the Compre-
hensive Addiction and Recovery Act (CARA), which became law in 
July 2016. CARA expanded buprenorphine prescribing privileges 
to nurse practitioners and physician assistants through October 
of 2021, although a they must complete a 24 hour training and 
must receive a DATA 2000 waiver from the DEA before they can 
legally prescribe buprenorphine. In many states, these providers 
will still need to be supervised by or work with a physician. Fi-
nally, CARA introduces flexibility to the limits on the number of 
patients to whom a given provider can prescribe buprenorphine 
(e.g., prescribers with existing limits of 100 patients can apply to 
have this limit raised to 275 patients, the HHS secretary has the 
option to exclude patients who receive medication directly at the 
point of service from the patient limit, etc.). 
 American Society of Addiction Medicine. Nurse Practitioners and 
Physician Assistants Prescribing Buprenorphine. Available from: 
http://www.asam.org/quality-practice/practice-resources/nurse-prac-
titioners-and-physician-assistants-prescribing-buprenorphine
 American Society of Addiction Medicine. Summary of 
the Comprehensive Addiction and Recovery Act. Avail-
able from: http://www.asam.org/advocacy/issues/opioids/
summary-of-the-comprehensive-addiction-and-recovery-act
xiv In 2005, DPH conducted a similar survey of 235 buprenorphine 
prescribers in Massachusetts, and identified similar barriers to 
expanding patient panels, indicating a need for increased insti-
tutional support. Walley AY, Alperen JK, Cheng, DM, Botticelli 
M, Castro-Donlan C, Samet JH, Alford, DP. Office-based man-
agement of opioid dependence with buprenorphine: Clinical 
practices and barriers. Journal of General Internal Medicine. 
2008(23): 1393-8. 
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Figure 14: Patientswhohavehadopioid-relatedhospitaldischargeswhowouldhaveto
travel more than 5 miles to access pharmacologic treatment 
Note: Hospital discharges include 
both ED and inpatient discharges. 
Traveldistancesaredefinedasthe
distancebetweenthepatient’szip
code of residence and the zip code 
of the nearest in-state provider. 
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In summary, data analyses on the impact of the opioid 
epidemic on hospitals, birthing centers, and the avail-
ability of pharmacotherapy providers highlight that the 
opioid epidemic is taking a substantial toll on the health 
care system. Between 2007 and 2014, opioid-related 
hospital discharges increased rapidly in Massachusetts. 
There is variable access to pharmacotherapy treatment 
throughout the state, but particularly for those residents 
in less populated regions of the Commonwealth who must 
travel long distances to access treatment. 
HPC EFFORTS TO ADDRESS 
THE OPIOID EPIDEMIC
The opioid epidemic, including increasing morbidity, 
mortality, and a growing toll on communities, highlights 
the need for improvements throughout the health care sys-
tem. Without timely access to evidence-based treatment, 
patients will continue to utilize high intensity settings of 
care for addiction treatment, both out of necessity and 
lack of other options. 
The HPC is working closely with other state agencies, 
providers, payers, and a variety of stakeholders to help 
the Commonwealth address the opioid epidemic through 
investments, care delivery certification programs, and a 
research and evaluation agenda that support the triple 
aim of improving health outcomes and patient experience 
while simultaneously reducing expenditures. The HPC’s 
care delivery vision calls for:
A health care system that efficiently 
delivers well-coordinated, patient-
centered, high-quality health care, 
integrates behavioral and physical 
health, and produces optimal health 
outcomes and health status.
Through its experience with health care investments, 
provider certification programs, and research and eval-
uation, the HPC has identified specific models of care 
that could be scaled and leveraged to increase the quality 
and efficiency of the Commonwealth’s response to the 
opioid epidemic, particularly the role of primary care 
providers (PCPs) in providing pharmacologic treatment 
to this population. These models of care fall broadly into 
four categories: 
1 behavioral health integration into primary care; 
2 fully integrated accountable care delivery systems; 
3 broad-based community coalitions; and
4 investments in innovative pilots.
INTEGRATING BEHAVIORAL HEALTH INTO 
PRIMARY CARE 
In Massachusetts, ~51% and ~86% of patients do not 
receive treatment for an existing mental illness or sub-
stance use disorder (SUD), respectively.38 Behavioral health 
disorders exacerbate the total cost of care (TCOC) for 
patients. For example, TCOC for patients with major 
depression and diabetes is 2 times higher than for patients 
with diabetes alone.39 
PCPs play a critical role in patient care by serving as the 
coordinators of care for timely and appropriate use of 
all health care services, including mental health and ad-
diction treatment. However, many PCPs are not trained 
to screen for or triage mental illness and/or SUD.40 The 
patient-centered medical home (PCMH) is one way to 
address this gap; the model uses a multi-disciplinary 
primary care-based team to provide comprehensive and 
coordinated care. The HPC is working to strengthen and 
support primary care practices in integrating behavioral 
health into primary care through its PCMH PRIME 
certification program.
PCMH PRIME layers 13 behavioral health integration 
criteria on top of the National Committee for Quality 
Assurance’s (NCQA’s) PCMH recognition standards, 
including screening for and treatment of opioid use dis-
order in the primary care setting.xv To be PCMH PRIME 
certified, a practice must meet at least 7 of the 13 PCMH 
PRIME criteria (Box 1) within a specified time frame, as 
well as be PCMH recognized by NCQA. 
xv http://www.mass.gov/anf/budget-taxes-and-procure-
ment/oversight-agencies/health-policy-commission/
certification-programs/
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Box 1: PCMHPRIMECertificationCriteria
Criteria (practice must meet ≥ 7 of 13)
The practice coordinates with behavioral healthcare 
providers through formal agreements or has behavior-
al healthcare providers co-located at the practice site.
The practice integrates behavioral health providers 
withinthepracticesite.
The practice collects and regularly updates a compre-
hensivehealthassessmentthatincludes behaviors 
affecting health and mental health/substance use 
history of patient and family.
The practice collects and regularly updates a compre-
hensivehealthassessmentthatincludes developmen-
tal screening for children under 3 years of age using a 
standardized tool.
The practice collects and regularly updates a compre-
hensivehealthassessmentthatincludes depression 
screening for adults and adolescents using a stan-
dardized tool.
The practice collects and regularly updates a com-
prehensivehealthassessmentthatincludes anxiety 
screening for adults and adolescents using a stan-
dardized tool.
The practice collects and regularly updates a compre-
hensive health assessment that includes SUD screen-
ing for adults and adolescents using a standardized 
tool.
The practice collects and regularly updates a compre-
hensive health assessment that includes postpartum 
depression screeningforpatientswhohaverecently
given birth using a standardized tool.
The practice tracks referrals until the consultant or 
specialist’sreportisavailable,flagging and following 
up on overdue reports.
The practice implements clinical decision support fol-
lowingevidence based guidelinesforamental health
and substance use disorder.
The practice establishes a systematic process and cri-
teriaforidentifyingpatientswhomaybenefit fromcare 
management. The process includes consideration of 
behavioral health conditions.
Thepracticehasatleastoneclinicianwhoisproviding
pharmacologic treatment (naltrexone, buprenorphine, 
and/ormethadone)and providing behavioral therapy 
directly or via referral, for substance use disorder.
The practice has at least one care managerqualifiedto
identifyandcoordinatebehavioralhealth needs.
The HPC will offer technical assistance to practices who 
commit to reaching PCMH PRIME status within 18 
months. HPC is working with Health Management As-
sociates to create, monitor, and manage the technical 
assistance program that addresses each of the 13 PRIME 
criteria and will be tailored to meet the needs of each 
practice. For example, practices aiming to provide phar-
macologic treatment for addiction could receive technical 
assistance in the form of clinical training and workflow 
redesign support to account for the additional tasks that 
accompany integrating addiction management into pri-
mary care (e.g., pill counts, urine toxicology screens). 
FULLY INTEGRATED ACCOUNTABLE CARE 
DELIVERY SYSTEMS
Integrated primary care is foundational for improving 
care for patients with complex behavioral and medical 
conditions, but accountable care organizations (ACOs) 
have the potential to support and sustain coordinated, 
comprehensive care beyond the boundaries of primary 
care. An ACO is generally defined as a group of physi-
cians, hospitals, and/or other providers whose mission 
is to improve health outcomes and quality of care while 
slowing the growth in overall costs for a specific popula-
tion of patients.41 
ACOs provide value by transforming care delivery through 
improvements in care coordination and integration, ac-
cess to services, and accountability for patient outcomes 
and costs. ACOs are designed to systematically integrate 
behavioral health treatment, primary care, and specialty 
services, and thus have the potential to play a vital role in 
promoting more efficient treatment of opioid use disor-
der. ACOs are supported by alternative payment models 
(APMs), such as global budgets, which incent the level of 
collaboration necessary between primary, specialty, and 
hospital-based care by putting the PCP system at risk 
for both TCOC and health outcomes. In other words, 
APMs incent providers to work together to organize 
the medication and behavioral therapy components of 
pharmacotherapy, as well as wrap around social supports, 
as necessary, for patients who struggle to engage with 
and/or remain in treatment. ACOs should play a critical 
role in coordinating post-discharge treatment for those 
individuals who are transitioning back to the community 
from incarceration or inpatient treatment, when patients 
are most vulnerable to overdose due to decreased opioid 
tolerance.42 
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The HPC has developed standards for ACOs in the Com-
monwealth to validate value-based care and promote 
investments by all payers in efficient, high-quality, and 
cost-effective care across the continuum. HPC ACO 
certification promotes system wide care coordination, 
including between transitions of care (e.g., from the ED 
to outpatient settings) and amoung different types of 
providers (e.g., community-based providers, addiction 
medicine, social services, and pediatrics). 
Through its ACO certification standards,43 the HPC 
seeks to promote continued transformation in care de-
livery while ensuring that certification is within reach 
for systems of varying sizes, organizational models (e.g., 
hospital-led, physician-led), infrastructure and technical 
capabilities, populations served, and geographic locations. 
Specific ACO certification criteria developed by the HPC 
to better meet the needs of patients with behavioral health 
conditions include:
• The ACO must routinely stratify its patient popula-
tion by risk and use the results to implement programs 
targeted at improving health outcomes for its highest 
need patients. At least one program must address 
behavioral health and at least one program must ad-
dress social determinants of health to reduce health 
disparities within the ACO population.
• To coordinate care and services across the care con-
tinuum, the ACO must collaborate with providers 
outside the ACO as necessary, including behavioral 
health providers, specialists, post-acute and long-term 
care, and hospitals. 
• ACOs should understand the needs and preferences 
of their patient population by routinely surveying 
social determinants of health (e.g. race, income, 
non-medical transportation needs, and food insecu-
rity) and develop programs with community-based 
social services organizations in order to better meet 
those needs. 
The HPC will develop technical assistance to support 
providers in developing models that meet its ACO certi-
fication standards with the intent of identifying and dis-
seminating best practices, including those around opioid 
use disorder prevention and treatment. Technical assistance 
for ACOs will be designed to foster and facilitate multi-
disciplinary care coordination that is patient-centered and 
accountable. This is critical with respect to improving the 
status quo of opioid use disorder treatment; patients will 
only be able to access timely and appropriate treatment 
when medical and behavioral health providers are held 
jointly accountable for overall patient health. 
BROAD-BASED COMMUNITY COALITIONS 
Working together with patients and families, primary care, 
community-based behavioral health providers, and local 
emergency professionals (e.g. police, fire, and emergency 
medicine services), community hospitals can play a critical 
role in improving access to pharmacologic treatment and 
behavioral health care for opioid use disorder. The HPC is 
working to increase access to opioid addiction treatment, 
in part, through its Community Hospital Acceleration, 
Revitalization, and Transformation Investment Program 
(CHART). CHART supports eligible Massachusetts com-
munity hospitals to enhance their delivery of efficient, 
effective care. Several CHART programs are helping to 
address the opioid epidemic by: 
1 assisting patients who present to the ED with an 
overdose to connect with treatment upon discharge 
(including preventing re-occurring overdose); and
2 improving retention in care by coordinating follow-up 
after hospital discharge. 
Early experiences of CHART-funded hospitals highlight 
the potential for broad-based community coalitions to 
implement locally-informed health system change. The 
following CHART projects transform care by enacting 
ED-based coordination of care that facilitates linkage to 
treatment for patients who present in emergency situations.
Berkshire Medical Center
Berkshire Medical Center is working to address social 
issues that lead to recurrent acute care utilization, provide 
enhanced care for patients with chronic conditions, and 
increase access to behavioral health services. CHART Phase 
2 funding is being used to support Berkshire in facilitating 
transitions to outpatient treatment from inpatient (acute 
or detoxification) and ED settings. 
The majority of services are based in the Neighborhood 
for Health program, an outpatient medical center pro-
viding comprehensive behavioral health, chronic disease 
management, and social services, in partnership with 
the co-located Substance Use Day Treatment Program of 
the Brien Center for Mental Health and Substance Abuse 
Services (Brien Center). Brien Center social workers and 
group clinicians work at the on-site day treatment center 
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and collaborate with Berkshire social workers to create a 
“bridge” to the buprenorphine services at the Brien Center 
(“Suboxone Bridge Program”). 
Berkshire is integrating the use of technology, such as 
telemedicine and enhanced electronic medical records, 
to support care coordination across treatment settings. 
Neighborhood for Health care navigators visit hospital-
ized patients to assess behavioral health and social needs 
for which care will be necessary upon discharge. If an 
appropriate candidate for pharmacologic intervention, a 
patient can use a televisit with the Neighborhood for Health 
psychiatrist to initiate buprenorphine treatment, who they 
then see (with the assistance of the care navigator) within 
1 day of discharge. 
Once at Neighborhood for Health, patients meet with a 
buprenorphine provider 2 to 3 times per week for up to 3 
weeks and participate in the Brien Center day program (or 
a similar evening program if an opening is not immediately 
available). Berkshire’s retail pharmacy provides benefit 
support to ensure buprenorphine coverage regardless of 
plan coverage, including reimbursement for the medica-
tion in cases where it is not covered.
Beth Israel Deaconess Hospital–Plymouth 
(BIDH–Plymouth)
In CHART Phase 2, BIDH–Plymouth (South Shore 
region) is working to reduce ED utilization for patients 
with a primary behavioral health diagnosis through its 
Integrated Care Initiative (ICI). The ICI program is de-
signed to address opioid use disorder through action at 
the individual, facility, and community levels by having 
the hospital lead efforts across outpatient providers (both 
primary and behavioral health) and in partnership with 
other community emergency professionals. 
At the individual level, the ICI provides patients with 
an addiction assessment in the ED. This is coupled with 
follow-up services and linkage to detoxification, outpatient 
pharmacotherapy, and primary care. 
At the hospital level, BIDH–Plymouth arranges for ex-
pedited referral from the ED to Clean Slate Centers and 
Harbor Health Services, both of which provide pharma-
cologic intervention (Harbor Health Services also provides 
primary care services). Additionally, ICI clinicians provide 
referrals to the Plymouth Drug and Mental Health Court 
for any patient with open charges that appear to be related 
to addiction. Patients not ready to engage in treatment 
are provided with information about recovery resources 
as well as follow up services through phone calls or a 
home visit, in an attempt to offer services post-discharge. 
All patients are provided with information on naloxone, 
including instructions on access and use. 
At the community level, the ICI collaborates with Project 
OUTREACH (Opioid User Taskforce to Reduce Epi-
demic and Care Humanely) led by the Plymouth Police 
Department in collaboration with the Carver and Mid-
dleboro Police Departments, behavioral health providers 
(e.g., CleanSlate, Gosnold, and High Point), and the 
Plymouth District Court. As part of this collaboration, 
clinicians (with a plain-clothes police accompaniment) 
are sent to patients’ homes following a naloxone reversal 
in the ED to encourage patients to seek treatment, as 
well as provide transportation directly to detoxification 
services. Through these community engagement visits, 
85% of patients accepted and entered treatment in the 
first 4 months of the program.
Hallmark Health System
Through its CHART Phase 2 award, Hallmark Health 
System (Melrose-Wakefield Hospital and Lawrence Me-
morial Hospital) located in the East Merrimack and 
Metro Boston regions of the Commonwealth, is seeking 
to reduce ED utilization in part by implementing its 
Collaborative Outreach and Adaptable Care at Hallmark 
Health (COACHH) program. COACHH targets 3 pa-
tient populations: patients with frequent recurrent use 
of the ED, obstetric patients with substance use disorder 
(SUD), and patients presenting with an opioid overdose 
requiring a naloxone reversal. The COACHH program 
is designed to improve Hallmark Health’s ability to meet 
the needs of opioid addiction at three levels: individual, 
community, and hospital. 
At the individual level, eligible patients are seen in the 
ED by a team of community health workers supported 
by a social worker to coordinate post-discharge follow-up 
care. Patients who elect to participate in the COACHH 
program are engaged by a multi-disciplinary care team, 
including a social worker, 3 community health workers, 
a pharmacist, a nurse practitioner, and PCPs. Following 
a discharge from the ED, COACHH team members 
follow-up with a phone call, text, and/or written letter 
over the next several days and weeks to ensure the patient 
is aware of COACHH services and to enroll him/her if 
interested. Patients are provided support in enrolling in 
detoxification programs as needed, and connected with 
pharmacologic treatment and behavioral health therapy. 
18 | Health Policy Commission
COACHH team members report that persistence in 
supporting patients over time, including those who are 
reluctant to engage in care, has proved critical to helping 
individuals initiate and adhere to treatment.
At the hospital level, Hallmark Health convened a sub-
stance use working group that is comprised of representa-
tives from senior leadership as well as from the pharmacy, 
community services, marketing and communications, 
behavioral health, psychiatry, emergency medicine, and 
emergency preparedness departments. This working group 
meets monthly to identify ways in which the hospital 
can reduce the incidence of opioid addiction, including 
hosting the SCOPE of Pain trainingxvi as part of a national 
training curriculum offered to providers and pharmacists 
on safe and effective pain management.
Finally, at the community level, the COACHH program 
is collaborating with local police and fire departments to 
identify patients in need of treatment. For example, the 
fire department alerts the COACHH team when a patient 
is being transported to the ED following overdose and 
naloxone reversal in the field. Additionally, the police 
department provides updates about individuals who may 
refuse transport to the ED following an overdose reversal. 
COACHH team members contact these individuals and 
offer the same supports that are offered when a patient 
is encountered in the ED. In one instance, the team 
successfully referred a patient to methadone treatment 
following multiple overdose reversals, even though the 
patient never presented at the ED. 
Harrington Memorial Hospital
Through its CHART Phase 2 award, Harrington Memorial 
Hospital aims to reduce recurrent ED utilization by in-
creasing access to cross continuum care for patients with a 
primary or secondary behavioral health diagnosis. Services 
include inpatient treatment for patients with co-occurring 
mental health and SUDs, a SUD intensive outpatient 
program, a partial hospitalization program, behavioral 
health screening and assessment across the hospital, and 
community-based follow-up. Harrington Memorial Hos-
pital has also partnered with the Dudley District Court to 
provide clinical support and case management for patients 
with opioid-related court involvement. Staff from Har-
rington Memorial Hospital regularly participate in case 
conferences for patients in the drug court program and 
xvi Additional information about available resources and materials for 
SCOPE of Pain training can be found at https://www.scopeofpain.
org/ 
provide the court with details of the patient’s enrollment 
and engagement with treatment services.
Recognizing the disparity in care for patients with SUD, 
Harrington Memorial Hospital has implemented an inte-
grated care model in the ED and inpatient units to screen 
patients for opioid use disorder, coordinate care with 
clinicians, and help patients engage with SUD and men-
tal health treatment providers in the community. Social 
workers and care navigators provide supportive care across 
the continuum of care in the hospital and post discharge. 
This integrated care model enables caregivers to tailor care 
to the needs of the patient rather than requiring patients 
to navigate different services and insurance requirements 
without assistance. Harrington Memorial Hospital has 
also increased education for staff on addiction treatment, 
with the underlying goal of treating opioid use disorder 
and other SUDs with the same intensity and care as any 
other acute psychiatric issue. 
HealthAlliance Hospital
Serving a catchment area severely impacted by the opioid 
crisis, HealthAlliance Hospital is using its CHART Phase 
2 award to improve ED workflow processes and follow-up 
services through the use of risk stratification strategies. A 
health evaluation and comprehensive intake assessment 
are performed by a team of care coordination specialists, 
who educate patients about the Health Integrated Col-
laborative Care Coordination (HIc3) team. 
HIc3 services include the scheduling of follow-up ap-
pointments, discharge planning, providing patients with 
primary care and behavioral health referrals, and long-
term care follow up. Patients who present to the ED with 
a primary and/or secondary behavioral health diagnosis 
or concern receive a brief screening while still in the ED 
(when possible), and are triaged to a dedicated CHART 
area within the hospital for further assessment. The HIc3 
team makes at least three attempts to follow up with 
patients that were missed while in the ED. For those 
patients that have previously declined services, the HIc3 
team attempts to engage the patient at least once after 
discharge and every subsequent ED visit thereafter.
Once enrolled in the HIc3 program, patients are transi-
tioned to community-based services with service intensity 
stratified by assessed need. The HIc3 team notes two early 
challenges and corresponding successes in serving opioid 
dependent patients: initial difficulty in achieving follow-up 
contact with this patient population and an inadequate 
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supply of available referral sources (e.g., detoxification 
beds, pharmacologic treatment providers) for a growing 
demand. 
INVESTING IN INNOVATIVE MODELS OF CARE
The HPC is investing nearly $10 million in multiple 
areas of innovation to encourage the testing and scaling 
of promising models of care delivery that improve access 
to and/or quality of behavioral health. Several of these 
funding opportunities target aspects of the opioid use 
disorder epidemic, including opioid-exposed newborns, 
innovative care delivery models to better coordinate care 
across medical, social, and behavioral care, telemedicine 
to increase access to providers, models that accelerate 
initiation of treatment, and data driven initiatives that 
improve provider performance.
Mother and Infant-Focused NAS 
Interventions
There are a number of proven, innovative care delivery 
models to improve care for pregnant and post-partum 
women with opioid use disorder and infants born with 
neonatal abstinence syndrome (NAS), a diagnosis that is 
growing in prevalence due to increased rate of in utero 
exposure to opioids. The following hospital-based ex-
amples have realized significant reductions in the use of 
pharmacologic treatment, LOS, and/or TCOC:
• Boston Medical Center realized reduced LOS for 
infants with NAS by 3.5 days (25.1 to 21.6 days) 
and total cost of care by approximately $9,000 per 
patient after implementing a quality improvement 
initiative that included resident education on NAS, 
nurse training on NAS scoring, and implementing 
protocols to reduce the number of infants receiving 
pharmacologic intervention (especially more than 1 
pharmacologic agent), and increasing the number of 
infants swaddled in sleep sacks.44
• Dartmouth Children’s Hospital (New Hampshire) 
reduced the percent of infants with NAS treated with 
pharmacologic intervention by 21%, average LOS 
for infants treated with morphine for NAS by 4.6 
days (18.2 to 13.6 days), and average TCOC by over 
$8,000 after implementing a quality improvement 
initiative that included nursing education, prenatal 
parent education programming, introduction of cud-
dlers into nurseries, and rooming-in.45
• Nationwide Children’s Hospital (Columbus, Ohio) 
saw a 36 day reduction in LOS over 5 years after cre-
ating an NAS taskforce and implementing a quality 
improvement initiative that included the introduction 
of standardized treatment protocols and nurse training 
on NAS severity scoring.46
• Yale New Haven Hospital (New Haven, CT) intro-
duced the use of non-pharmacologic interventions 
including low-stimulation rooms, swaddling, feed-
ing on demand, and rocking. These interventions 
yielded a decrease in LOS from 28 days to 8.5 days 
between 2003 and 2015 for patients in the NICU, 
a decrease in pharmacologic treatment from 98% to 
44%, a reduction in pharmacologic dosage by 50% 
for those requiring pharmacologic intervention, and 
a total savings of $5.4 million between 2011-2015 
(attributed to decreased LOS and reduction in mor-
phine treatment).47
To promote the adoption of cost-effective and high quality 
treatment of NAS like the examples above, the HPC is 
investing over $4 million in hospital quality improvement 
initiatives that drive toward reducing TCOC between the 
delivery and discharge of opioid exposed newborns. The 
HPC is coordinating its efforts with DPH by expanding 
on a federal grant awarded to DPH from SAMHSA that 
seeks to identify pregnant women with opioid use disorder 
and promote collaborations between outpatient providers 
(e.g., obstetricians, PCPs, behavioral health providers) to 
increase engagement and improve retention in addiction 
treatment for pregnant and post-partum women. HPC 
and DPH are also building a technical assistance program 
for birthing hospitals across the state to disseminate best 
practices in the care of NAS and retention in opioid use 
disorder treatment. 
Targeted Cost Challenge Investments
HPC’s Targeted Cost Challenge Investments (TCCI) 
program will fund both payers and providers to collaborate 
in novel ways that increase access to and efficiency of care. 
This includes over $4.5 million in care delivery models 
that increase access to SUD and mental health treatment. 
These innovations will improve care coordination across 
providers and improve access to treatment. For example, 
HCII awardees will target patients with co-morbid and 
complex medical and behavioral health diagnoses, using 
patient navigators to steer patients who tend to over uti-
lize emergency settings into primary care, and providing 
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bedside addiction consults for hospitalized patients with 
comorbid conditions.
Telemedicine
The HPC is investing nearly $1.8 million in telemedicine 
innovations that enhance community-based access to be-
havioral health services for residents of Massachusetts with 
unmet behavioral health needs, approximately one quarter 
of which will target patients with SUD. Telemedicine 
has a number of applications48 that have demonstrated 
success in improving health outcomes and reducing acute 
care utilization, without sacrificing patient experience of 
care.49 Telemedicine can facilitate direct interaction be-
tween providers themselves, and between providers and 
patients, or allow for remote monitoring programmed to 
alert a provider when intervention is necessary.
HPC’s investments in telemedicine will fund, in part, a 
model that increases access to SUD treatment by funding 
bedside consults and post-discharge follow-up for patients 
hospitalized with co-morbid medical and SUD diagnoses 
who are not receiving treatment for their addiction. 
Although the strongest evidence base for telemedicine 
treatment of SUD is limited to alcohol use disorder, there 
is no contraindication for its application to opioid use 
disorder.50 Testing the utility of telemedicine treatment 
for opioid use disorder is the only way to establish its ef-
ficacy, and is a critical policy tool to address an epidemic 
complicated by workforce shortages. 
ED-based Initiation of Buprenorphine 
Treatment 
Studies have shown that buprenorphine’s immediate im-
pact on opioid seeking behavior (reduced craving) increases 
engagement and retention in treatment. For example, 
when initiated in an ED setting (e.g., after an overdose), 
patients are significantly more likely to follow up with 
outpatient treatment, remain sober 30 days after discharge, 
and are less likely to require inpatient addiction treatment 
as compared to patients discharged with referral to treat-
ment only (i.e., without medication).51 Nonetheless, no 
EDs in the Commonwealth, to the HPC’s knowledge, are 
currently administering the first 72 hours of a buprenor-
phine dose. The HPC will invest in supporting EDs to 
adopt this practice, evaluate its results and disseminate 
lessons learned (the state legislature reallocated up to $3 
million from the Distressed Hospital Trust Fund for the 
HPC, in consultation with DPH, to implement a 2-year 
pilot program).
Because ED providers can only prescribe the first 72 
hours of buprenorphine treatment, prompt follow-up 
with a buprenorphine prescriber is critical. Thus, close 
collaboration between EDs and outpatient providers is 
crucial to the success of ED initiation of buprenorphine. 
The HPC’s investment in this area will require hospitals 
to demonstrate partnerships that will facilitate referral to 
and connection with outpatient buprenorphine providers 
and behavioral therapy. 
Data-Driven Provider Performance 
Improvement
A previous HPC investment in Hallmark Health System 
through the CHART program allowed the organization to 
test the efficacy of making data available to providers, in-
cluding their own prescribing data and the extent to which 
they use decision making support tools. Hallmark Health 
System had identified substantial variation in opioid 
prescribing patterns after reviewing nearly 1,000 medical 
records. As it assumed accountability for TCOC across 
providers within its health system, Hallmark used HPC 
funding to conduct trainings on opioid prescribing best 
practices and to implement provider-facing “dashboards” 
that displayed prescribing patterns of themselves and their 
peers. The dashboards illustrated each ED provider’s rate 
of prescribing and utilization of the Prescription Drug 
Monitoring Program (PDMP). Hallmark’s two hospitals 
experienced a reduction in opioid prescription rates – by 
26% at Melrose-Wakefield and by 43% at Lawrence Me-
morial (Appendix 7). 
The HPC’s work to transform the Massachusetts health 
care system into an accountable and integrated model 
includes: (1) research and evaluation; (2) certification 
programs that promote integration of behavioral and 
physical health; and (3) investments that incent adoption 
of innovative models of care. In collaboration with payers, 
providers, other state agencies, and the legislature, the 
HPC promotes policy advancements that will further 
support a movement towards a transparent and highly 
efficient system of care.
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POLICY RECOMMENDATIONS 
These policy recommendations are informed by the anal-
yses published in this report as well as current HPC work. 
They are strategically aligned with ongoing work across 
the Commonwealth to address the opioid epidemic, iden-
tifying areas where the HPC’s role in health care reform 
can add value to the myriad efforts to slow the rate of 
opioid related morbidity and mortality. 
Recommendation 1: The Commonwealth should sys-
tematically track the impact of the opioid epidemic 
on the health care system and the availability of evi-
dence-based pharmacologic treatment.
As rates of opioid overdoses continue to increase at an 
unprecedented rate in the Commonwealth, hospitals face 
growing pressure, both in ED and inpatient settings. To 
appropriately address the epidemic, the state must priori-
tize data collection – on hospitals experiencing the greatest 
volume of opioid-related discharges, on the availability 
of evidence-based pharmacologic treatment providers 
(both prescribers and behavioral health providers), and 
on health outcomes (e.g. rate of relapse, length of stay, 
breastfeeding rates for infants with NAS). 
This report identifies areas of the Commonwealth where 
patients are experiencing opioid-related complications 
that result in hospital discharges at the highest rates. 
Systematic tracking of hospital discharges and outpatient 
provider supply (including wait list times), particularly 
at the municipal level, are critical to informing the ap-
propriate allocation of resources throughout the health 
care system and in communities disproportionately af-
fected by the epidemic. The HPC is beginning this work 
both by tracking the impact of the opioid use disorder 
on hospitals, conducting an analysis on availability of 
dual-diagnosis providers across the Commonwealth, and 
developing recommendations on increasing supply and 
accessibility, as necessary. 
To ensure quality is systematically assessed, the Common-
wealth should consider development of another dashboard 
to track outcomes and benchmark treatment performance 
for both opioid use disorder and NAS. This will allow 
the state to identify and promote those treatments that 
are most effective, scalable, and sustainable.
Recommendation 2: The Commonwealth should 
increase access to and effectiveness of evi-
dence-based opioid use disorder treatment by inte-
grating pharmacologic interventions into systems 
of care.
Given the significant and growing burden of opioid-re-
lated illness on hospitals – both on EDs and in inpatient 
settings – the Commonwealth must increase access to 
timely evidence-based treatment in order to reduce the 
rate at which patients are overdosing, as well as turning 
to high intensity settings for treatment and complications 
of opioid use disorder and overdose. Access to evidence 
based pharmacologic treatment and behavioral therapy 
is proven to facilitate long-term recovery, reduce relapse, 
and thereby reduce hospital utilization.xvii 
Moreover, the Commonwealth could increase access to 
evidence-based treatment by promoting integration of 
addiction treatment into primary care, as well as incenting 
health care systems to facilitate access to and coordinate 
pharmacotherapy and behavioral health services. For ex-
ample, ACOs should be appropriately incented to contract 
with an adequate number of behavioral health providers 
to provide a full continuum of care. Moreover, it is critical 
that ACOs are adequately motivated by payment model 
accountability to provide the social supports (e.g., trans-
portation, peer support) necessary to enable patients to 
successfully engage in and remain in treatment. 
Payers should support ACOs, including behavioral health 
providers and PCPs, by adequately reimbursing for the 
additional staffing resources necessary for compliance with 
regulatory requirements (e.g., urine toxicology screens, 
pill counts), as well as for increased care coordination 
and management that is necessary for the provision of 
pharmacologic treatment of addiction. 
xvii The Commonwealth is working on several initiatives that would 
promote this goal, including a section 1115 Demonstration Waiver 
(1115 waiver) submitted to the Centers for Medicare & Medicaid 
Services (CMS), and a planning grant awarded by the Department 
of Health and Human Services to assist a number of state agencies 
in certifying behavioral health providers as Certified Community 
Behavioral Health Centers (CCBHCs). The state’s 1115 waiver 
would make all SUD services Medicaid reimbursable, including 
those that are currently only reimbursed through BSAS (e.g., TSS 
and RRS), as well as fund peer-support services, dual diagnosis 
services, and the use of the Screening, Brief Intervention and 
Referral to Treatment (SBIRT) model in primary care settings. 
Massachusetts’ CCBHC initiative would incent behavioral health 
providers to integrate primary care into settings where those 
with the most complex behavioral health needs seek treatment. 
For more information on both initiatives, see http://www.mass.
gov/eohhs/gov/commissions-and-initiatives/healthcare-reform/
masshealth-innovations/1115-waiver-proposal-information.html 
and http://mehi.masstech.org/ehealth/tour-specialty/ccbhc.
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a) Payers should support the integration of 
addiction treatment into primary care
Although methadone can only be administered in stand-
alone federally licensed opioid treatment programs, bu-
prenorphine and naltrexone prescribing can both be 
integrated into the primary care setting, with appropriate 
coordination (or direct provision) of counseling and other 
behavioral health therapy. Integration of pharmacologic 
treatment into the primary care setting, including coor-
dination or direct provision of behavioral therapy, will 
increase the number of prescribers delivering this ser-
vice. Since 2006, the Bureau of Substance Abuse Services 
(BSAS), within DPH, has been funding office based opioid 
treatment-buprenorphine (OBOT-B), which utilizes an 
evidence-based, integrated, primary care delivery model 
at federally qualified health centers (FQHCs) throughout 
the Commonwealth.52
PCPs prescribing buprenorphine require expanded staff-
ing case management capacity to comply with regulatory 
requirements around minimizing diversion and improper 
use. Absent additional financial support, PCPs maintain-
ing full patient panels lack capacity to adjust workflows 
accordingly. Payers should account for the cost of these 
additional provider and case management tasks and re-
ward PCPs for quality (i.e.., link payment to metrics such 
as reduced addiction related admissions and relapses, 
shorter wait times for treatment initiation, and fewer 
days missed work). 
b) Payers should ensure adequate networks of 
community-based behavioral health providers 
to improve access to community-based care
Improving access to community-based behavioral health 
providers is an essential element of improving opioid use 
disorder outcomes. These providers must not only be 
available, but also have collaborative working relationships 
with hospitals and PCPs to facilitate effective coordination 
of varying levels of care. The Commonwealth should 
both incent ACOs to contract with these providers, as 
well as track availability to identify areas of particularly 
salient need.
c) Payers should support initiation of 
addiction treatment in acute care settings 
in coordination with accountable, integrated 
systems of care
Patients who present to EDs because of an opioid-related 
overdose are at high risk of relapsing upon discharge unless 
they are immediately connected with addiction treatment. 
Initiation of buprenorphine in the ED, before discharge, is 
proven to increase the rate at which patients engage with, 
and remain in, treatment as compared to patients who 
are simply referred to treatment upon discharge.53 Payers 
could promote effective treatment of opioid use disorder 
by incenting health care systems to initiate buprenorphine 
in the ED, in coordination with follow up outpatient 
treatment. Public and private efforts to transform health 
care delivery and payment models should be designed 
to encourage meaningful collaboration across the care 
continuum and coordination with non-medical services. 
d) Payers should facilitate the collaboration 
between providers of different levels of care 
to minimize loss to follow-up during transitions 
between settings.
Patients seeking treatment for opioid use disorder may 
require a number of services across the care continuum 
(e.g., detoxification services, residential treatment, in-
tensive outpatient treatment, pharmacologic treatment, 
behavioral counseling). Payers can help to reduce gaps 
in treatment by working closely with providers to move 
patients efficiently between settings of care and tracking 
them to ensure there are not waiting periods between 
treatment modalities that make relapse more likely.
Recommendation 3: The Commonwealth should 
support coordinated, multi-stakeholder commu-
nity coalitions to address the impact of the opioid 
epidemic locally.
The intensity of the opioid epidemic and the configura-
tion of local resources varies across the Commonwealth. 
As demonstrated by the success of the HPC’s CHART 
program initiatives, it is clear that broad-based com-
munity coalitions are critical to stemming the tide of 
the opioid epidemic. The Commonwealth should sup-
port community-based efforts that coordinate across all 
sectors—hospitals, public health departments, payers, 
outpatient providers, pharmacies, law enforcement, the 
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corrections system, schools, and social supports. Further, 
the Commonwealth should support community coalitions 
in identifying best practices, disseminating learnings, and 
evaluating outcomes at the local level. Such coalitions 
not only prevent the duplication of individual sector 
efforts, but leverage shared-learnings among multiple 
community stakeholders to exact a coordinated front 
against the epidemic. BSAS has funded two such coa-
litions since 2008: the Massachusetts Collaborative for 
Action, Leadership, and Learning (MassCALL2) and the 
Massachusetts Opioid Abuse Prevention Collaborative 
(MOAPC).54,55 Both receive funding from SAMHSA and 
distribute grants throughout the Commonwealth for the 
purpose of combating opiate abuse and overdose. 
Recommendation 4: The Commonwealth should 
test, evaluate, and scale innovative care models for 
treating opioid use disorder and related conditions.
As the Commonwealth works to respond to the grow-
ing opioid epidemic, the state should support providers 
in the testing, evaluation, and scaling of emerging best 
practices with respect to treatment of opioid use disorder, 
as well as conditions that emerge as a byproduct of the 
epidemic (e.g., neonatal abstinence syndrome, or NAS). 
This includes further testing of models such as ED-based 
initiation of buprenorphine and coordination of follow 
up care, scaling of innovative models of NAS treatment, 
using telemedicine to increase access to pharmacotherapy 
and behavioral therapy, and making practice pattern data 
readily accessible to providers to facilitate performance 
improvement. Due to the rapid pace at which this disease 
is affecting large numbers of patients, investing in and 
measuring the outcomes of innovative models of care is 
critical to identifying an effective response to the epidemic. 
a) ED-based initiation of buprenorphine 
treatment
As the Commonwealth supports the evidence-based initia-
tion of buprenorphine in the ED, coupled with outpatient 
follow up and coordination of care, it should continue 
to monitor outcomes and best practices, given the na-
scent nature of this care model. The HPC will invest in 
community hospitals to support implementation of this 
practice, partnering with outpatient providers that have 
demonstrated capacity to assure timely follow up after 
discharge.56 Results from this initiative can inform state 
efforts to scale similar supports that have been shown to 
increase engagement and retention in treatment, as well as 
reduce rates of relapse, readmissions, and ED utilization.
b) Mother & Infant Focused Neonatal 
Abstinence Syndrome (NAS) Interventions
Infants exposed to opioids in utero are often treated in the 
highest intensity settings of care, despite evidence that the 
neonatal intensive care unit is often not the best option. 
Strategies associated with reduced cost of care (without 
decreases in quality) include reducing pharmacologic 
intervention (e.g., methadone, morphine) and making 
naturally soothing treatment modalities available. For 
example, allowing an infant to “room-in” with the birth 
mother, frequent feeding, using breast milk when possible; 
swaddling, and minimizing exposure to stimuli (e.g., low-
noise, dim lighting) are proven to result in reduced total 
LOS as well as a reduction in the need for placement in 
a NICU, thereby decreasing expenditures significantly.57 
The Commonwealth, including payers, should support 
and incent hospitals to adopt these practices, as well as con-
tinue to monitor the prevalence, intensity, and outcomes 
related to NAS throughout the state. Tying payment to 
improved quality and efficiency could reduce the burden 
of the growing rate of NAS on TCOC across the state. 
c) Telemedicine
The Commonwealth could employ telemedicine as one 
strategy to increase access to pharmacotherapy. For ex-
ample, PCPs can use telemedicine to link patients to 
licensed social workers who can provide tele-therapy and 
to connect with addiction medicine providers as expert 
consults on complex patients. Payers should support 
access to telemedicine services through APMs or as a 
billable service in order to facilitate access to treatment 
and establish a stronger evidence base for the utility of 
telemedicine with respect to opioid use disorder and rates 
of treatment adherence, relapse, and hospital utilization. 
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CONCLUSION 
Increased rates of opioid overdoses have resulted not only 
in increased mortality, but also an escalation in rates of 
emergency department utilization and hospital discharges, 
taking a tremendous toll on the Commonwealth’s health 
care system. Building on the recent efforts to combat the 
opioid epidemic, this report identifies ways in which the 
Commonwealth could further address the opioid epidemic 
in ways that relate to the HPC’s mission – increasing 
transparency and accountability of the health care system. 
While no one solution exists, preventing opioid overdoses 
and increasing access to addiction treatment requires a 
multi-pronged approach that encompasses coordinated 
efforts among local communities, courtrooms, police and 
fire departments, schools, and the health care system. This 
report has focused only on the latter, given the HPC’s 
charge, but does not diminish the tremendous importance 
of other prongs of intervention. 
Through this report, the HPC seeks to add value to the 
wide-ranging activities already in motion by identifying 
areas where the HPC’s role in health care reform can 
be leveraged as part of the Commonwealth’s efforts to 
combat opioid use disorder. The report identifies ways 
in which the state can drive innovation and promote 
an accountable care system that adequately addresses all 
health conditions, rather than only physical diagnoses. 
It is critical that the Commonwealth establish a strategy 
to systematically track the impact of the opioid epidem-
ic. Specifically, it will be important to not only monitor 
mortality rates, but also to monitor the health care system, 
communities, and the availability of evidence-based phar-
macotherapy. Moreover, the state’s support for integration 
of opioid use disorder treatment into primary and acute 
care, including by implementing alternative payment 
models, and investments in innovative approaches that 
improve treatment availability and/or efficiency, will be 
essential to alleviating strain on the Commonwealth’s 
health care system and reducing unintended opioid re-
lated mortality. 
DATA NOTES
For purposes of this report, opioid-related hospital dis-
charges were identified in the Center for Health Informa-
tion and Analysis (CHIA) Hospital Inpatient Discharge 
Database, Outpatient Observation Database, and Emer-
gency Department Database, using ICD-9 diagnoses codes 
designated by the United States Department of Health 
and Human Services, Agency for Healthcare Research 
and Quality.58 Discharges with opioid-related diagno-
sis codes, primary or otherwise, were included in this 
analysis. These opioid-related diagnosis codes include: 
304.00-304.03 (opioid type dependence), 304.70-304.73 
(combinations of opioid type drug with any other drug de-
pendence),305.50-305.53 (nondependent opioid abuse), 
965.00 965.01, and 965.09 (poisoning by heroin, opium 
(alkaloids), and related narcotics), E850.0 and E850.2 
(accidental poisoning by other opiates and related nar-
cotics), E935.0 and E935.2 (heroin and other opiates 
causing adverse effects in therapeutic use). Note, as of 
2014 there was no specific diagnosis code for fentanyl. 
For more details, please see the Technical Appendix.
Notably, this methodology is distinct from that used by 
the Massachusetts Department of Public Health (DPH), 
which estimated that in 2013 more than 2,000 hospital 
discharges and 4,500 ED discharges were associated with 
opioid use disorder. DPH used a narrower set of ICD-9 
codes: 965.00-965.02, 965.09 (poisoning by opiates) 
and E850.0-E850.2 (accidental poisoning by opiates).59 
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APPENDICES
Appendix 1: MandateoftheGovernor’sOpioidAddictionWorkingGroupandMembers
In June 2015, Governor Baker’s Opioid Addiction working group, an 18 member committee tasked with identifying 
ways to address the opioid epidemic, released 65 recommendations, which are being implemented now and over the 
next 3 years, as appropriate. 
Members of the Opioid Working Group: 
• Marylou Sudders, Secretary, Executive Office of 
Health and Human Services
• Maura Healey, Attorney General
• George Bell, General Catalyst Partners
• Monica Bharel, MD, MPH, Commissioner of the 
Department of Public Health
• Bill Carpenter, Mayor of Brockton
• Colleen Labelle BSN, RN-BC, CARN, Program 
Director of the State Technical Assistance Treatment 
Expansion Office Based Opioid Treatment with Bu-
prenorphine program at Boston Medical Center; 
Executive Director of the Massachusetts chapter of 
the International Nurses Society on Addictions.
• Alan Ingram, Ed.D., Deputy Commissioner, Mas-
sachusetts Department of Elementary and Secondary 
Education
• Judy Lawler, Probation Officer, Chelsea District 
Drug Court
• Joseph D. McDonald, Sheriff, Plymouth County
• John McGahan, The Gavin Foundation
• Fred Newton, President & CEO of Hope House, Inc.
• Robert Roose, MD, MPH, Chief Medical Officer 
of Addiction Services at the Sisters of Providence 
Health System
• Cindy Steinberg, National Director of Policy & Ad-
vocacy, U.S. Pain Foundation; Chair, Policy Council, 
Massachusetts Pain Initiative
• Ray Tamasi, President and CEO of The Gosnold 
on Cape Cod
• Steve Tolman, President, Massachusetts AFL-CIO
• Sarah Wakeman, MD, Medical Director, Substance 
Use Disorders, Center for Community Health Im-
provement, Division of General Medicine, Depart-
ment of Medicine, Massachusetts General Hospital
• The Honorable Paula M. Carey, Chief Justice of 
the Trial Court
• The Honorable Rosemary B. Minehan, Plymouth 
District Court
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1.1:RecommendationsfromtheGovernor’sOpioidAddictionWorkingGroup(June2015)xviii
The Baker administration plans to spend $34.5 million to implement these recommendations (detailed below), 
which include:
• $800,000 for a public awareness campaign
• $5.8 million to move substance use disorder treatment out of prison and into Taunton State Hospital
• $14 million for recovery beds
• $5 million for school-based education
• $3 million for case managers and coordinators at MassHealth
Recommendations Related to Treatment Time Frame
RealignTreatmentSystemtoReflectNatureofOpioidUseDisorderasaChronicDiseasewithPeri-
ods of Acute Needs and Periods of Stability 
• Increase points of entry to treatment, eliminating the need for individuals to access other levels 
ofcareonlythroughacutetreatmentservices(ATS)andclinicalstabilizationservices(CSS)
• Establish and promote a longitudinally based treatment system and continuum of care 
1 – >3 yrs. 
Increase Treatment Access by Matching Demand and Capacity
• Developareal-time,statewidedatabaseofavailabletreatmentservices,makinginformation
available via phone and the internet
• Increasethenumberofpost-ATS/CSSbeds(transitionalsupportservice,residentialrecovery
homes)
• Fund patient navigators and case managers to ensure a continuum of care
• Pilotaprogramthatprovidespatientswithaccesstoanemergentorurgentaddictionassess-
ment by a trained clinician and provides direct referral to the appropriate level of care
• Establishrevisedratesforrecoveryhomes,effectiveJuly1,2015
6 mos. – 3 yrs.
Increase Access to Evidence-Based Medication-Assisted Treatment
• Increasethenumberofoffice-basedopioidtreatmentprogramsandthenumberofpractitioners
prescribing buprenorphine and naltrexone
• Enforce and strengthen the requirement that all licensed addiction treatment programs accept 
patients on an opioid agonist therapy
6 mos. – 3 yrs.
Promote Integration of Mental Health, Primary Care, and Opioid Treatment
• CreateaconsistentpublicbehavioralhealthpolicybyconductingafullreviewofallDPHand
DMH licensing regulations for outpatient primary care clinics, outpatient mental health clinics, 
and BSAS programs removing all access barriers
• Explore state mechanisms to establish opioid treatment programs as Health Homes
• ConductareviewofthelicenserenewalprocessforprogramsaccreditedbyTheJointCommis-
sionorCommissiononAccreditationofRehabilitationFacilities(CARF)andevaluatewhether
Massachusettsshouldimplementa“deemedstatus”forBSASlicenserenewals
• Permitclinicianstoholdanindividualwithasubstanceusedisorderinvoluntarilyinordertocon-
ductanassessmentofwhetherreleaseposesalikelihoodofseriousharm
6 mos. – >3 yrs.
xviii http://www.mass.gov/eohhs/docs/dph/stop-addiction/recommendations-of-the-governors-opioid-working-group.pdf
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Recommendations Related to Youth & Parent Education & Interventions Time Frame
Support the implementation of substance use prevention curricula in schools. School districts 
should have the autonomy to choose the evidence-based curricula and the grade level that it is im-
plemented in their district. Programs must be proven to reduce nonmedical opioid use. Examples 
of programs include: LifeSkills and All Stars
6 mos. – 1 yr.
Integrate information about the risks of opioid use and misuse into mandatory athletic meetings 
and trainings for parents, students, and faculty 6 mos. – 1 yr.
Increase the use of screenings in schools to identify at-risk youth for behavioral health issues 1 – 3 yrs.
Develop targeted educational materials for school personnel to provide to parents about closely 
monitoringopioiduseiftheirchildisprescribedopioidsafteraninjury,aswellas,signsandsymp-
toms of drug and alcohol use
6 mos. – 1 yr.
Partnerwithstateuniversitiesthathavestrongeducationprogramstodevelopsubstanceuse
preventioncurriculaforschooldistrictsthroughouttheCommonwealth 1 – 3 yrs.
Require state universities that educate teachers to integrate screening and intervention tech-
niquesaswellassubstanceusepreventioneducationintothecurriculum 1 – 3 yrs.
Recommendations Related to Neonatal Abstinence Syndrome, Prenatal Care & Neonatal Care Time Frame
Outreach to prenatal and postpartum providers to increase training about: screening, intervention, 
andcareforwomenwithasubstanceusedisorder 6 mos. – 1 yr.
Promoteearlyidentificationandpropertreatment,raiseawarenessofNASwithinthepublichealth
and medical communities 1 – 3 yrs.
Reviewthecostsandbenefitsofmandatingtestingforinuteroexposuretoalcoholanddrugsat
every birth 6 mos. – 1 yr.
Ensureadequatecapacityforpregnantwomeninthetreatmentsystem 6 mos. – 1 yr.
Develop and institute a training program focused on NAS and addiction for Department of Children 
andFamiliesstaff 1 – 3 yrs.
WorkwithhealthcareproviderstoensureallinfantswithNASarereferredtoearlyinterventionby
the time of hospital discharge 1 – 3 yrs.
Partnerwithearlyintervention(EI)leadershipanddevelopmentalexpertstostudythevalueof
increasingautomaticEIeligibilityforinfantswithNASfromoneyeartotwoyears –
Recommendations Related to Prescriber & Safe Disposal Practices Time Frame
Mandate pain management, safe prescribing training, and addiction training for all prescribers 
as a condition of licensure (physician assistants, nurses, physicians, dentists, oral surgeons, and 
veterinarians)
1 – 3 yrs.
Allowpartialrefillsacrossallpayerswithaone-timeco-payment 1 – 3 yrs.
EliminateprescriptionrefillsbymailforscheduleIImedications 1 – 3 yrs.
ImprovethePrescriptionMonitoringProgram(PMP):
• Increase utilization by improving ease of use and expanding abuse alerts from the PMP to pre-
scribers
• EnsuredatacompatibilityofthePMPwithotherstates&interfacethePMPwithelectronichealth
records
• Enforce mandatory use of the PMP
• RequirePMPdatatobesubmittedwithin24hoursbypharmacies
• Improvedataanalyticsandeducateprescribersabouthowtoutilizetheinformation
6 mos. – >3 yrs.
Implement electronic prescribing for opioids 1 – 3 yrs.
Partnerwiththemedicalandprovidercommunitytoimproveandincreaseeducationalofferings
for prescribers and patients to promote safe prescribing 6 mos. – 1 yr.
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Promoteawarenessandsupportforalternatepaintherapies >3 yrs.
Appointindividualswithexpertiseinaddictiontothemedicalprofessionlicensingboards –
Develop universal distribution of easy to read materials at pharmacies on the safe use of medica-
tions –
Expandandpromotedrugtake-backdaysandpermanentdrugtake-backlocations,financedby
pharmacies and manufacturers –
Requirepractitioners,includingdentists,toeducatepatientsontherisksandsideeffectsassoci-
atedwithopioidsanddocumentsuchdiscussionsatthepointofprescribing 1 – 3 yrs.
Increase screening for substance use at all points of contact in the medical system 1 – 3 yrs.
Appoint members to the drug formulary commission established under Chapter 258 of the Acts of 
2014 6 mos. – 1 yr.
Recommendations Related to Reframing Addiction as a Disease Time Frame
Createapublicawarenesscampaign,withmessagingthattargetsvariousages,focusedon:
• Reframing addiction as a medical disease
• Promoting medication safety practices
6 mos. – 1 yr.
PromotetheGoodSamaritanlaw 6 mos. – 1 yr.
Reduce stigma among medical and treatment professionals >3 yrs.
Recommendations Related to Enhancing the Utilization of Data to Improve Transparency Time Frame
Require and support universal and timely reporting of overdose deaths, through a partnership 
betweentheDepartmentofPublicHealth,theAttorneyGeneral’sOffice,theMassachusettsState
Police, the District Attorneys, local police departments, emergency medical services, hospitals, 
and others
6 mos. – 1 yr.
Make EMS overdose data available 6 mos. – 1 yr.
Utilize overdose reports to identify geographical hot spots for targeted intervention and to alert 
lawenforcement,publichealthentities,communitycoalitions,andthepublic 6 mos. – 1 yr.
CreateaunifiedEOHHSprivacypolicyandimplementaprocessforsharingconfidentialdata –
Recommendations Related to Government & Provider Accountability Time Frame
EstablishasinglepointofaccountabilityfortheCommonwealth,DirectorofAddictionandRecov-
ery Policy 6 mos. – 1 yr.
Enhance provider accountability by requiring treatment programs at all levels (inpatient and outpa-
tient)toreportonoutcomes 1 – 3 yrs.
Incentivize and support providers to develop and test innovative treatment approaches –
Create provider accountability for the successful transition from one level of care to the next and 
incentivizeproviderstoreducere-admissions;thecurrent“system”inadvertently“rewards”provid-
ers for repeat detoxes and rehabs
–
Require the Department of Public Health to advance standards of care by establishing industry 
benchmarks 1 – 3 yrs.
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Recommendations Related to the Court Time Frame
Increase drug and specialty court capacity 1 – 3 yrs.
Increaseaccesstobedsforpatientswhoarecivillycommittedundersection35ofchapter123of
theGeneralLawsandprovidearosterofcurrentlyavailablebedstojudgesforsection35commit-
ments
1 – 3 yrs.
Reviewandrevisedischargepoliciesforsection35patients;facilitiesmustberequiredtofollow
thelawandissueawrittendeterminationthatreleasewillnotresultinalikelihoodofseriousharm
whenindividualsaredischargedfromthefacility
6 mos. – 1 yr.
Improve the continuum of care for patients committed under section 35 1 – 3 yrs.
EnsurenotificationtotheCourtwhenasection35patientescapesfromtreatment 6 mos. – 1 yr.
Recommendations Related to Policing & Correctional Institutions Time Frame
Transfer responsibility for civil commitments from the Department of Corrections to the Executive 
OfficeofHealthandHumanServices 6 mos. – 1 yr.
Suspend, rather than terminate, MassHealth coverage during incarceration 6 mos. – 1 yr.
Partnercorrectionalfacilitieswithcommunityhealthcenterstoensureindividualscanaccess
treatment upon release –
Analyze treatment spending in correctional facilities
• Inmatesshouldbeabletocontinuemedication-assistedtreatmentwhileincarcerated
• Inmatesshouldbeabletobegintreatmentwhileincarceratedandbeconnectedtotreatment
upon release
6 mos. – 1 yr.
Encourage and support alternatives to arrest, making police a partner in obtaining treatment for 
individuals 6 mos. – 1 yr.
Bulk purchase opioid agonist and naltrexone therapies for county corrections 6 mos. – 1 yr.
Recommendations Related to Recovery & Support Time Frame
Leverage and increase support for community coalitions to address the opioid crisis
• Create an online repository of resources and best practices for community coalitions
• Improvestatewidecoordinationandinformationsharingamongcoalitions
1 – 3 yrs.
Expand peer and family support organizations such as Learn to Cope 1 – 3 yrs.
Pilot recovery coaches in emergency rooms and hot spots 6 mos. – 1 yr.
Implement a process to certify alcohol and drug free housing to bring accountability and credibility 
to this recovery support system 6 mos. – 1 yr.
Partnerwithbusinessestoremoveemploymentbarriersthatrecoveringindividualsexperience,
specificallyreviewregulationsrelatedtoCORIchecks 1 – 3 yrs.
Incentivize employers to hire individuals in early recovery 1 – 3 yrs.
Toimproveoutcomesforrecovery,explorethebenefitsandcostsassociatedwithissuingcertifi-
cates of recovery 6 mos. – 1 yr.
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Recommendations Related to Naloxone Time Frame
Investigate the feasibility of having Naloxone in public spaces 6 mos. – 1 yr.
ImproveaffordabilityofNaloxone
• Through bulk purchasing agreements
• By eliminating all copayment requirements
1 – 3 yrs.
EncourageNaloxonetobeco-prescribedwithopioids 6 mos. – 1 yr.
Recommendations Related to Insurance Time Frame
Require the Division of Insurance to implement guidance for commercial insurers about the imple-
mentationofchapter258oftheactsof2014priortoOctober1,2015 6 mos. – 1 yr.
Eliminate insurance barriers that impede integration of addiction and mental health care into the 
primary care setting >3 yrs.
Require consistent coverage and prior authorization practices and policies throughout all Mass-
Health programs –
Bringmeaningtofederalandstatebehavioralhealthparitylawsthroughenforcementactionsto
remove inappropriate barriers to treatment –
Encourage insurers to support non-opioid pain therapies >3 yrs.
Prepareapublicreportonwhatnon-pharmacologictreatmentsforpainarecoveredbyallprivate
and public insurers >3 yrs.
Encourageinsurerstosupportrecoverycoachesforindividualswithasubstanceusedisorder 6 mos. – >3 yrs.
Encourageinsurerstosupportnewpathwaystotreatment >3 yrs.
Recommendations Related to Federal-State Partnerships Time Frame
PartnerwithfederalleaderstorecommendthattheAmericanCollegeofGraduateMedicalEduca-
tion adopt requirements for pain management and substance use disorder education for all medi-
cal and residency programs (i.e. surgical, pediatrics, internal medicine, family medicine, obstetrics, 
andgynecology)
1 – 3 yrs.
PartnerwithfederalleaderstorecommendthattheCommissiononDentalAccreditationadopt
requirements for education on safe opioid prescribing practices for all dental programs –
PartnerwithfederalleaderstorecommendthattheAmericanVeterinaryMedicalAssociation
adopt requirements for education on safe opioid prescribing practices for all veterinary programs –
Partnerwithfederalleaderstoincreasesupportforsubstanceuseprevention,intervention,treat-
ment,andrecoveryeffortsuniquelytailoredforourveterans –
RequesttheDrugEnforcementAgency(DEA)topermitmedicalresidentstoprescribebuprenor-
phineunderaninstitutionalDEAregistrationnumber,thusallowingresidentstolearnhowtoman-
agepatientswithanopioidaddiction
–
Implementnationwidestandardsforpharmaceuticaltakebackprograms
•Requiremanufacturersandpharmaciesnationwidetofinancethedisposalofunusedprescription
medication
–
Changethelawsandregulationsrelatedtoprescribingbuprenorphine
• Increase the cap - the number of patients a physician can treat - or remove it entirely
• Permit nurse practitioners and physician assistants to prescribe buprenorphine
–
Facilitatetheinteroperabilityofprescriptionmonitoringprogramsnationwide 1 – 3 yrs.
Review42CFRPartIItoensurethatitfacilitatesintegratedcareandtheuseofelectronichealth
recordsanddoesnotexacerbatethestigmaassociatedwithasubstanceusedisorder >3 yrs.
Request that the Pain Management Question from the HCAHPS not be linked to hospital reim-
bursement –
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1.2:UpdatesfromtheGovernor’sOpioidAddictionWorkingGroup(asofJanuary2016)
Updates from the Governor’s Opioid Working Group (January 2016)xix
Prevention
July 2015
• SupplementalbudgetrequestfiledbyGovernorBakerfor$27.8milliontoaddressthe
opioidcrisis($5millionforpreventioneducation)
• DPH sponsors free training for 138 people on evidence-based substance use prevention
• MAHospitalAssociationpublishesnewscreeningtoolforevaluatingpatientswithsub-
stance use disorders
August 2015
• ParticipantsinDPHtrainingreceivesecondevidence-basedskillstrainingin“Botvin
LifeSkills”
• DrugFormularyCommissionholdsfirstmeeting
• MA Medical Society publishes physician treatment and communication guideline and CME 
webinarsonpainmanagementandjudiciousprescribing
• DPH publishes informational material for parents
September 2015 • 133 sites participate in National Drug Take-Back Day to collect unneeded prescriptions
October 2015
• GovernorBakerfilesH.3817,whichaimstoincreasesaccesstotrainingforproviders,
treatmentforpeoplewithsubstanceusedisorders,preventioneducation,amongothers
• GovernorBakerandMayorWalshurgeMALegislaturetopassH.3817
• DPH sponsors free training for school nurses on evidence-based substance use preven-
tion
November 2015 • DCF/BSASbeginstrainingsonNAS• GovernorBakerlaunches“#StateWithoutStigMA”campaign
December 2015 • DPH and MA Interscholastic Athletic Association launch partnership to provide parents and coaches educational material on opioids
February 2015 • “BotvinLifeSkills”trainingsscheduledforschoolnursesandpersonnelthroughMarch2016
Intervention
July 2015 • Ch.46ofactsof2015signedintolaw,creatingabulkpurchasingtrustfundandregulationsregarding compulsory use of PMP
August 2015
• DPH issues overdose death data to public in August quarterly report
• AGHealeynegotiatesagreementwithAmphastarfor$325,000togointobulkpurchase
trust fund
September 2015 • DPH urges pharmacies to distribute opioid prescription drug fact sheet• DPHCommissionerurgesprescriberstoco-prescribenaloxonewithopioidprescriptions
October 2015
• DPH releases overdose death data to public in October quarterly report 
• BSASpostsRFRforpilotprogramsfocusedonincreasingaccesstowalk-intreatmentand
appropriate referrals
November 2015 • DPHissuesguidancetotownsandcitiesonhowtoutilizeCommonwealthMunicipalNalox-one Bulk Purchase Trust Fund
December 2015
• DPH requires pharmacies to submit data on dispensing controlled substances to PMP (105 
CMR700.012)
• DPH opens PMP for use by medical residents and interns
• HPCannounces$3.5milliontoimprovecareforNAS
• DPHawardscontracttoAppriss,Inctoimplementanew,enhancedPMP
xix http://www.mass.gov/eohhs/docs/dph/stop-addiction/action-plan-update.pdf
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Treatment
June 2015 • 10 adult residential recovery home beds added in Westborough• 2 Clinical Stabilization Service beds added in Fall River
July 2015
• MassHealthissuesnewprotocolstoensureeligibleindividualsreceivecoverageupon
release from incarceration
• DPH issues alert to all DPH providers, contractors, and stakeholders clarifying all addiction 
treatment programs must accept patients receiving MAT
• GovernorBaker’s$27.8millionsupplementarybudgetrequesttoinclude$5.8millionto
transferwomencommittedunderSection35atMCI-FraminghamtoTauntonState,and$3
million to MassHealth to increase services
• MassHealthbeginstofast-trackenrollmentforqualified,uninsuredDPHclientsreceiving
detoxificationservices
• DPH,DMH,andDivisionofInsuranceissuesnewguidanceonimplementationofCh.258
August 2015
• BSAS and MA League of Community Health Centers discuss strategies for increasing num-
berofproviderswithDEAwaiverstoprescribebuprenorphine
• DPHreceives3-year,$3millionSAMHSAgranttoexpandMATandcomprehensiveser-
vicesforpregnantwomenwithopioidusedisorders
• MassHealthandDPHcommittocreatestatewidedatabaseofrelevanttreatmentservices,
to be complete in early 2016
• Celticare removes prior authorization requirements for Suboxone
• 125 beds licensed by DMH opened in Dartmouth
September 2015
• 11detoxificationbedsand8ClinicalStabilizationServicebedsopenedinPlymouth
• MassHealthnotifiesallMCOstoremovepriorauthorizationforcertainsubstanceuse
treatment services
• 23 adult residential recovery home beds added in Westborough
• US HHS announces revisions to buprenorphine prescribing restrictions
October 2015 • 15adultresidentialrecoveryhomebedsaddedinLowell• 22 adult residential recovery home beds added in Boston
November 2015
• MassHealthissuesguidelinestocontractedhealthplansonhowtoreducebarriersto
treatment,specificallyMAT
• BSASpostsRFRtoincreaseoffice-basedopioidtreatmentprogramsincommunityhealth
centers
• Governor,deansoftheCommonwealth’smedicalschool,andMAMedicalSocietylaunch
newcorecompetenciesinprimary,secondary,andtertiarypreventionandmanagementof
drug misuse 
• MA League of Community Health Centers holds conference for over 70 suboxone pre-
scriberswithworkshopsaboutchronicpainandaddiction
• 20 Clinical Stabilization Service beds added in Haverhill
December 2015 • 23detoxificationbedsaddedinHaverhill• DPH posts RFR to pilot recovery coaches in ED
January 2016
• DPHannounces$466,450ingrantsawardedtofourproviderorganizationstoimprove
treatmentforyouthandyoungadultswithco-occurringdisorders
• DPHawards$700,000ingrantsto31municipalitiestosupportcarryingandadministering
naloxonebypoliceandfiredepartments
• DPHawards$6.8millioningrantsto16communitiestoimplementevidence-basedpre-
ventionprograms,policies,andpracticestargetedtoward12to25yearolds
• 24ATSbedsaddedinBoston
• 28section35treatmentbedsforwomenscheduledtoopeninShattuck
February 2016 • 32ATSand32CSSbedsscheduledtoopeninGreenfield• 15section35treatmentbedsforwomenscheduledtoopeninTauntonStateHospital
Spring 2016
• MassHealth plans to take steps to ensure Outpatient Treatment Programs that dispense 
methadonehavetheabilitytobillMassHealthforbuprenorphineandnaltrexoneinaneffort
to expand access to MAT
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Recovery
July 2015 • $27.8supplementalbudgetrequestincludes$14milliontoincreasecompensationratesinrecoveryhomesforindividualswithsubstanceusedisorders
September 2015 • Recovery High School in Worcester opens
October 2015
• DPHawardstwocontractsforvoluntarysoberhomecertificationprocess
• Dailyratecompensationratesinrecoveryhomesforindividualswithsubstanceusedisor-
dersincreases,andwillbepaidretroactivelytoJuly2015
October to  
December 2015 • DPHhosts3trainingsforresidentialtreatmentproviders,andtrains147individuals
January 2016 • Recovery Home Collaboration and MA Association of Sober House begin to certify sober homes
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Appendix 2: Summary of recommendations of Special Senate Committee on Opioid Addiction 
Prevention, Treatment, and Recovery Options60
After holding a number of hearings, the Special Senate Committee on Opioid Addiction Prevention, Treatment 
and Recovery Options issued a set of recommendations, in September 2015, to strengthen prevention of opioid use 
disorder, intervention, treatment, and recovery options in the Commonwealth.61 Below is the list of the committee’s 
members followed by a summary table of its findings and recommendations. Note that many of these provisions were 
incorporated into recent legislation, namely Ch. 52 of the Acts of 2016, An act relative to substance use, treatment, 
education and prevention.
Jennifer L. Flanagan (Chair) 
Worcester and Middlesex District 
Special Committee Chair
John F. Keenan 
Norfolk and Plymouth District 
Special Committee Vice Chair
Michael O. Moore 
Second Worcester District
Richard J. Ross 
Norfolk, Bristol and Middlesex  
District
Eric P. Lesser 
First Hampden and Hampshire 
District
Anne M. Gobi 
Worcester, Hampden, Hampshire 
and Middlesex District
Viriato M. deMacedo 
Plymouth and Barnstable District
Joan B. Lovely 
Second Essex District
Kathleen O’Connor Ives 
First Essex 
Recommendations excerpted from the Report of the Special Senate Committee on  
Opioid Addiction Prevention, Treatment, and Recovery Options
Training and Awareness of Good Samaritan Provisions:  
EstablishGoodSamaritanAwarenessprogramasarequiredelementofMunicipalPoliceTrainingCommittee(MPTC)
basictrainingcurriculumandasaperiodicallyreviewedsubjectforin-servicetraining.
Drug Formulary List of Non-opiate Pain Management Products:  
DirectthenewlyformedDrugFormularyCommission(whichexiststodevelopBrandv.Generic,andAbuse-deterrent
v.Non-abusedeterrentsubstitutionlists)toalsopublishalistofnon-opiatepainmanagementproductsthatmaybe
usedaslowerriskalternatives.
Voluntary Non-opiate Directive: 
(a)DirectEOHHStoestablishavoluntaryprogramforanypersontorecordanon-opiatedirective.Thiswouldallowa
person in recovery, or for any other reason of personal choice, to have a clear indicator in their patient record and in 
thePMP,thatahealthcarepractitionerorhealthcarefacilityshallnotadminister,offerorprescribeopiatedrugsto
that person. 
(b)Apersoncanhavetheirownnon-opiateorderdeletedandexpungedforanyreason.
(c)Recordingofanon-opiatedirectivewouldbeonastandardizedformpublishedbyEOHHS,andtheformmust
complywithallfederalrequirementsforprivacyofaddictiontreatmentrecords.Theformmustalsopresentplain
languageinformationonhowtoremovetheorder.
(d)Regulationstoimplementtheprogrammustcoverhealthcareproxyandguardianshipoverrideofthenon-opiate
directive, and the ability for treating clinicians to override the directive in an emergency situation and based on 
documentedmedicaljudgment.Shouldalsoincludeexemptionsforemergencypersonnelactinginthefieldduring
an emergency.
Expanded SBIRT Screening: 
(a)LocalschooldepartmentsorboardsofhealthshallrequireSBIRTscreeningatleastonceannuallyforallstudents
in grades 8 or 9, and in grade 11. These screenings shall be performed by a nurse, physician, or other personnel 
approved for the purpose by the DPH. 
(b)Screeningresultsshallberecordedwithoutidentifyinginformation,andreportedtotheDPH.
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Safeguards on High Risk Drugs: 
(a)Chapter258of2014taskedtheDrugFormularyCommissionwithidentifyinghigh-riskextended-release/long-act-
ingdrugsandalertingthepublichealthcommissioner,butthefinalversiondidnotincludeanycorresponding
authority to act or any further safeguards on these high-risk products. 
(b)Thisbillwouldlimitopioidprescriptionsinanemergencydepartmenttoa5-daysupply,andwouldprohibitan
EDfromissuingprescriptionsfortheidentifiedhigh-riskdrugs.Itwouldalsorequirethatprescriptionsofthese
high-riskproductsbeissuedonlyonadeterminationthatlowerriskdrugsareunsuitable,andwithapainmanage-
menttreatmentagreementinplace.Themedicaldeterminationwouldbedocumentedandplacedinthepatient’s
medicalfile.
(c)LanguagehereissimilartowhatwaspassedintheSenateversionlastyear,withregardto“heightenedrisk”drugs
identifiedbytheformularycommission.
Patient Choice in Prescription Volume: 
(a)Legislationwouldallowpatientstovoluntarilyreducethequantityofanopiatedrugthattheyreceive,regardlessof
the quantity indicated on their prescription. 
(b)Pharmacistswouldberequired,intheirroutineconsultationwithapatient,toadvisethemofthisoption.The
pharmacistwouldbeauthorized,withnofurtherapprovalfromtheprescriberormodificationoftheprescription,to
dispense the drug in a partial quantity. 
(c)Noticeofthepartialprescriptionwouldberecordedandsenttotheprescriberinareasonabletime,andthere-
mainingquantityontheprescriptionwouldremainvalidfor72hourspursuanttofederalregulations.
(d)Insurancecarrierswouldberequiredtooffercost-sharingonaslidingscalebasedonquantity,toaccommodate
forapatientwhovoluntarilyreceivesalesserquantity.
Drug Stewardship: 
(a)Establish,asaconditionofsellingordistributingascheduleIIorIIIdruginMassachusetts,thatthemanufacturerof
thedrugestablishandfundastewardshipprogramthatallowspatientstodisposeofunusedandunwanteddrugs.
(b)Exemptionsareincludedforveterinaryproducts,drugscompoundedonaper-patientbasis,sharpsproducts
whosedisposalisalreadycoveredunderexistingMGL,anddrugsapprovedforuseinmedicationassistedaddic-
tion treatment. 
(c)Stewardshipplanswouldberequiredtoincludeadrugtake-backormail-backcomponent;adequateprovisions
for the security, transport and disposal of returned products; provisions to incentivize participation; and public 
outreach and education. 
(d)PlanswouldbeapprovedbytheDepartmentandrenewedeverythreeyears,withtheabilitytoassessfinesfor
violationsordiscontinuationofthestewardshipplan,andwithrepeatviolationsbeingsentforwardtotheAttorney
Generalforenforcement.
Individual Prescriber Trend Notifications: 
(a)UtilizePMPdatatolearnmoreaboutthemeanandmedianprescribingvolumesforopiatesinMassachusetts,and
subsequentlybuildindividualprescriberprofilesshowingeachprescribertheirpercentilewithregardtotheirpeers.
(b)Profileswouldbeconfidential,sharedonlywiththeprescriberasaneducationaltooltohelpthemshapetheirown
practices.Thiswouldprovideobjectivedataaboutprescribingtrendsandbestpractices,ratherthanhavingpre-
scribers rely on "guidance" from pharmaceutical sales teams about appropriate prescribing practices.
Access to Pain Management Specialty Consultation: 
(a)DirecttheBoardofRegistrationinMedicinetocreateapainmanagementspecialtycertification.Thiswouldnot
restrictthecurrentpracticeofanyonenotcertified,butitwouldidentifypractitionerswhocanprovidespecialized
consultations. 
(b)Establishacommissionthatwilldeveloppainmanagementconsultationandtemporaryserviceguidelines,mirror-
ingthemodeloftheMCPAPprogramforchildpsychiatry.Thiswouldallowpractitionerstoleveragetheexpertise
of their peers, making greater use of the currently limited number of pain management specialists.
36 | Health Policy Commission
Review of Coverage For Non-narcotic Pain Management: 
(a)LegislationfromthecommitteecouldincludearequirementfortheDivisionofInsurancetoreviewpainman-
agement options; for insurance carriers to develop a pain management plan and post information on their public 
websiteaboutalternativepainmanagement.
(b)Legislationcouldalsoincludearequirementforinsurancecarrierstodevelopcontrolmethodsagainstoverpre-
scribingandoverrelianceonpainmedication,andtopostthisplanontheirpublicwebsiteaswell.
(c)PainmanagementplanandcontrolledsubstancesafetyplanwouldbothbecomeapartoftheexistingDOIaccred-
itation process.
Transparency in Addiction Service Denial Rates: 
(a)Requireannualreportingondeniedclaimsbyeachinsurancecarrier,categorizedbymedical/surgicalandbehavior-
al/addiction.
(b)Requirethat,witheachdenialofaninternalgrievancecaserelatingtobehavioral/addiction,thecarriermustspecif-
ically describe the medical necessity criteria and treatment limitations relied upon for the denial.
Civil Liability Protection for Narcan Administration: 
Massachusettscurrentlyprovides“GoodSamaritan”legalprotectiontoanypersontopossessandadministernalox-
one.However,thisprotectiondoesnotextendtocivilliability.Closingthisgapmayremovethehesitationsofsome
firstresponderagenciesthathavenotyetadoptedtheuseofthislifesavingproduct.
Gabapentin Monitoring: 
RequirethatGabapentin–adrugthatisincreasinginpopularityforitsenhancingeffectonopiatemisuse–bereport-
ed and monitored by the Prescription Monitoring Program.
MassHealth Lock-In Program Correction: 
(a)Chapter244of2012includedasectioncodifyingthe“Lock-In”programunderMassHealth.However,inapplication
andinterpretationtherearetwogapsthatcanbeaddressed.
(b)Thelock-inprogramisintendedtolimitpatients,uponfindingofcertainriskindicators,toasinglepharmacyand
asingleprescriberfortheircontrolledsubstances.ThelanguageinChapter244hasbeeninterpretedtoonlylimit
patients to a single pharmacy, not to restrict the number of prescribers. 
(c)Currently,patientswhoreceivecoveragethroughanMCOandareenrolledinalock-inprogramareremovedfrom
lock-in if they move from one MCO to another. This could be amended so that the person remains in the program 
regardless of an MCO change.
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Appendix 3: SummaryoftheCenterforHealthInformationandAnalysis’SUDReport
As required by Section 30 of Chapter 258 of the Acts of 2014, the Massachusetts Center for Health Information 
and Analysis (CHIA) published its Access to Substance Use Disorder Treatment in Massachusetts report in April 2015.62 
CHIA’s report describes the continuum of care for SUD treatment in Massachusetts and evaluates available coverage 
options for those services across payers including commercial health insurance plans, MassHealth, and the Bureau of 
Substance Abuse Services (BSAS). CHIA’s report examines the accessibility of SUD services along the care continuum 
based on provider availability, potential barriers to accessing treatment and the capacity of providers to appropriately 
meet the treatment needs of the SUD patient population. The report categorizes treatment and access issues in 4 
categories (prevention, intervention, treatment, and recovery). 
CHIA’s Continuum of Care in MA: Definitions, Examples, Coverage
Category Examples Funding/Coveragexx
Prevention
Community-focused initiatives to educate the 
public (e.g., radio and television public health 
campaigns)
Often aim to restrict youth access to substances
Largely funded and administered by BSAS
Intervention
BSAS’sOverdoseEducationandNaloxoneDistri-
bution program
Learn2Cope
Family Intervention pilot programs
DPH Prescription Monitoring Program
Typically funded by BSAS (including 
subcontracting to consumer advocacy 
groupsandtreatmentorganizations)
Treatment
Inpatientdetoxificationcenters
Inpatient and outpatient Clinical Support Services 
and Transitional Support Services
Medication Assisted Treatment (e.g., methadone, 
buprenorphine,naltrexoneforopioidaddiction)
Funded by commercial insurers, Mass-
Health,and/orBSAS
Recovery
Substance-freewalk-inRecoveryandSupport
Centerswithpeermentoringandsupport
Recovery high schools
Sober housing
BSAS covers recovery high schools
xx May include out-of-pocket spending, private foundation support, government grants, donations and other forms of support.
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CHIA’s report also highlights gaps in treatment in the state, including inadequacy of services, long waiting lists, and 
geographic spread of providers. To address these issues, in part, chapter 258 eliminated prior authorization for patients 
receiving acute treatment services and stabilization services for the first 14 days of treatment, and MassHealth prohibits 
cost-sharing for SUD inpatient services.xxi, 63 The table below provides a summary of coverage, capacity, cost-sharing, 
and expected additional capacity for given treatments.
Capacity, coverage, and cost-sharing for given treatments
Program Type Capacity Coverage &  Cost-Sharing
Acute treatment services 
(ATS - detoxification)
Hospital-based:4programs;150totalbeds
Free-standing: 20 programs; 710 total beds (serve approx. 
3500patientspermonth)
Free-standing Section 35: 2 programs; 56 total beds
Anticipatedexpansion:32bedsinGreenfieldandseveral
pending licensure applications 
Commercial($69-$500
for24hrs)
MassHealth 
BSAS
Continuing support ser-
vices (CSS - stabilization)
Non-Section 35: 11 programs; 297 total beds (approx. 600 
patientsservedpermonth)
Section35:2programs;142totalbeds
Anticipatedexpansion:32bedsinGreenfield
Commercial($69-$500
for24hrs)
MassHealth
BSAS
Transitional support ser-
vices (TSS - stabilization)
Non-Section 35: 9 programs; 339 total beds (approx. 331 
patientsservedpermonth)
Section 35: 2 programs; 80 total beds
Anticipatedexpansion:4beds
BSAS
Outpatient Counseling 
(ongoing treatment)
119 programs
Unknownnumberofindependently-practicingbehavioral
health clinicians
Commercial (co-pays 
rangefrom$16-$31)
MassHealth
BSAS
Medication assisted 
treatment (MAT - ongoing 
treatment)
39 Methadone Opioid Treatment Programs
677DEAcertifiedphysiciansthatcanadministerbuprenor-
phineto100patientsperyear(innon-specialtysettingonly)
16BSASsupported/staffedoffice-basedopioidtreatment
programs in community health centers that administer 
buprenorphine and naltrexone
Unknownnumberofproviderscanprescribe/administer
naltrexone(notethatHPCsurveyidentifiednumber–see
section4)
Commercial (co-pay-
ments for methadone 
average$20-$30per
visit)
MassHealth 
BSAS
Long-Term Residential 
(ongoing treatment)
Adult Residential: 79 programs; 2281 total beds
Family Residential: 8 programs (serve approximately 110 
familiesatatime)
AdolescentResidential(age13-17):6programs;105total
beds 
Youth Residential: 2 programs; 30 total beds (serve approxi-
mately600patientspermonth)
BSAS
xxi Chapter 258 prohibits plans governed by state law from imposing prior authorization requirements on SUD treatment, which may obviate 
providers concerns about prior authorization being a barrier to prescribing any type of pharmacologic therapy for opioid use disorder, 
although it remains to be seen whether prior authorization will continue to be required for higher doses. For more information, see: https://
malegislature.gov/Laws/SessionLaws/Acts/2014/Chapter258
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Appendix 4: Opioid-relatedhospitaldischargesbycity/town,2014
The following table presents the number of opioid-related 
hospital discharges in each city and town. City/town is 
based on patient’s resident zip code, not hospital address. 
This appendix is meant to serve as an analog to DPH’s 
opioid-related mortality database.xxii 
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Abington 166
Acton 52
Acushnet 62
Adams 98
Agawam 119
Allston 88
Amesbury 171
Amherst 56
Andover 76
Arlington 114
Ashburnham 22
Ashby 14
Ashfield Fewerthan11
Ashland 76
Ashley Falls Fewerthan11
Assonet 23
Athol 93
Attleboro 475
Attleboro Falls Fewerthan11
Auburn 62
Auburndale 30
Avon 32
Ayer 77
Baldwinville 21
Barnstable 13
Barre 36
xxii For opioid-related deaths by city and town, see http://www.mass.
gov/eohhs/docs/dph/quality/drugcontrol/county-level-pmp/
town-by-town-listings-january-2016.pdf 
xxiii HPC Analysis—CHIA, Hospital Inpatient Discharge Database 
and Emergency Department Database, 2014
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Becket 21
Bedford 35
Belchertown 71
Bellingham 79
Belmont 48
Berkley 49
Berlin 12
Bernardston Fewerthan11
Beverly 414
Billerica 219
Blackstone 26
Blandford Fewerthan11
Bolton 15
Bondsville 13
Boston 3,353
Bourne 26
Boxborough 15
Boxford 15
Boylston 16
Braintree 271
Brewster 37
Bridgewater 145
Brighton 163
Brimfield 14
Brockton 1,744
Brookfield Fewerthan11
Due to terms of HPC’s data use agreement with CHIA, 
where there were fewer than 11 ED visits and hospital 
discharges combined in 2014 in a given city or town, the 
exact number is not made publicly available. 
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City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Brookline 81
Buckland Fewerthan11
Burlington 139
Buzzards Bay 141
Byfield 12
Cambridge 479
Canton 130
Carlisle Fewerthan11
Carver 134
Cataumet Fewerthan11
Centerville 62
Charlemont Fewerthan11
Charlestown 162
Charlton 52
Chatham 23
Chelmsford 91
Chelsea 286
Cherry Valley Fewerthan11
Cheshire 19
Chester Fewerthan11
Chesterfield Fewerthan11
Chestnut Hill 32
Chicopee 716
Chilmark Fewerthan11
Clinton 133
Cohasset 34
Colrain 12
Concord 20
Conway Fewerthan11
Cotuit 25
Cummington Fewerthan11
Dalton 106
Danvers 233
Dedham 255
Deerfield Fewerthan11
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Dennis 19
Dennis Port 48
Devens Fewerthan11
Dighton 22
Dorchester 236
Dorchester Center 506
Douglas 31
Dover Fewerthan11
Dracut 202
Drury Fewerthan11
Dudley 48
Dunstable Fewerthan11
Duxbury 35
East Bridgewater 136
East Brookfield Fewerthan11
East Falmouth 222
East Freetown 23
East Longmeadow 68
East Otis Fewerthan11
East Sandwich 26
East Taunton 71
East Walpole 16
East Wareham 71
East Weymouth 208
Eastham 23
Easthampton 132
Edgartown 30
Erving Fewerthan11
Essex 15
Everett 568
Fairhaven 106
Fall River 1,237
Falmouth 85
Fayville Fewerthan11
Feeding Hills 105
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City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Fiskdale 12
Fitchburg 480
Florence 62
Forestdale 19
Foxborough 90
Framingham 412
Franklin 145
Gardner 141
Georgetown 37
Gilbertville Fewerthan11
Gill Fewerthan11
Gloucester 367
Goshen Fewerthan11
Gosnold Fewerthan11
Grafton 25
Granby 45
Granville Fewerthan11
Great Barrington 46
Greenfield 189
Groton 27
Grove Hall 224
Groveland 27
Hadley 26
Halifax 76
Hampden 20
Hanover 64
Hanscom Fewerthan11
Hanson 64
Hardwick Fewerthan11
Harvard 11
Harwich 40
Harwich Port Fewerthan11
Hatfield 15
Haverhill 911
Haydenville Fewerthan11
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Heath Fewerthan11
Hingham 68
Hinsdale 39
Holbrook 178
Holden 72
Holland Fewerthan11
Holliston 32
Holyoke 803
Hopedale 29
Hopkinton 50
Housatonic Fewerthan11
Hubbardston 18
Hudson 100
Hull 110
Humarock Fewerthan11
Huntington 16
Hyannis 249
Hyde Park 198
Indian Orchard 100
Ipswich 64
Jamaica Plain 264
Jefferson Fewerthan11
Kingston 57
Lakeville 67
Lancaster 38
Lanesborough 32
Lawrence 1,002
Lee 70
Leeds 40
Leicester 39
Lenox 12
Lenox Dale Fewerthan11
Leominster 340
Leverett Fewerthan11
Lexington 30
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City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Lincoln Fewerthan11
Littleton 33
Longmeadow 34
Lowell 1,200
Ludlow 190
Lunenburg 50
Lynn 1,185
Lynnfield 64
Malden 558
Manchester-by-the-
Sea 12
Mansfield 149
Marblehead 59
Marion Fewerthan11
Marlborough 165
Marshfield 145
Marstons Mills 66
Mashpee 146
Mattapan 180
Mattapoisett 30
Maynard 39
Medfield 16
Medford 432
Medway 54
Melrose 130
Mendon 18
Merrimac 50
Methuen 503
Middleborough 187
Middlefield Fewerthan11
Middleton 86
Milford 173
Millbury 80
Millers Falls Fewerthan11
Millis 42
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Millville Fewerthan11
Milton 75
Monroe Bridge Fewerthan11
Monson 85
Montague 20
Monterey Fewerthan11
Nahant 19
Nantucket 38
Natick 189
Needham 49
Needham Heights 20
New Bedford 1,297
New Braintree Fewerthan11
New Marlborough Fewerthan11
New Salem Fewerthan11
Newbury 18
Newburyport 96
Newton 45
Newton Centre 26
Newton Highlands 15
Newton Lower Falls 22
Newton Upper Falls Fewerthan11
Newtonville 31
Norfolk 52
North Adams 218
North Andover 91
North Attleboro 222
North Billerica 82
North Brookfield 22
North Chatham Fewerthan11
North Chelmsford 32
North Dartmouth 84
North Dighton 13
North Easton 89
North Falmouth 40
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City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
North Grafton 35
North Hatfield Fewerthan11
North Oxford Fewerthan11
North Reading 74
North Truro Fewerthan11
North Weymouth 108
Northampton 176
Northborough 37
Northbridge 36
Northfield 16
Norton 167
Norwood 403
Oak Bluffs 22
Oakham Fewerthan11
Orange 41
Orleans 26
Osterville Fewerthan11
Otis 11
Oxford 80
Palmer 135
Paxton Fewerthan11
Peabody 506
Pembroke 138
Pepperell 66
Petersham Fewerthan11
Pittsfield 959
Plainfield Fewerthan11
Plainville 83
Plymouth 457
Plympton 18
Princeton Fewerthan11
Provincetown 15
Quincy 999
Randolph 193
Raynham 107
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Reading 145
Rehoboth 34
Revere 630
Richmond 13
Rochdale Fewerthan11
Rochester 14
Rockland 289
Rockport 33
Rowe Fewerthan11
Rowley 21
Roxbury 58
Royalston Fewerthan11
Russell Fewerthan11
Rutland 19
Sagamore 13
Sagamore Beach 34
Salem 443
Salisbury 143
Sandisfield Fewerthan11
Sandwich 25
Saugus 347
Savoy Fewerthan11
Scituate 68
Seekonk 12
Sharon 50
Sheffield 29
Shelburne Falls 20
Sherborn Fewerthan11
Shirley 33
Shrewsbury 87
Shutesbury Fewerthan11
Somerset 103
Somerville 406
South Chatham Fewerthan11
South Dartmouth 69
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City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
South Deerfield 22
South Dennis 49
South Easton 89
South Ergemont Fewerthan11
South Grafton 34
South Hadley 104
South Hamilton 26
South Lee Fewerthan11
South Walpole Fewerthan11
South Weymouth 165
South Yarmouth 74
Southampton 31
Southborough 23
Southbridge 161
Southfield Fewerthan11
Southwick 34
Spencer 92
Springfield 1,787
Sterling 15
Stockbridge Fewerthan11
Stoneham 182
Stoughton 247
Stow 13
Sturbridge 28
Sudbury 20
Sunderland Fewerthan11
Sutton 19
Swampscott 70
Swansea 82
Taunton 716
Templeton 17
Tewksbury 219
Three Rivers 33
Topsfield 29
Townsend 49
City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
Truro Fewerthan11
Turners Falls 71
Tyngsboro 38
Tyringham Fewerthan11
Upton 16
Uxbridge 53
Vineyard Haven 32
Waban 11
Wakefield 228
Wales Fewerthan11
Walpole 99
Waltham 382
Ware 141
Wareham 152
Warren 19
Warwick Fewerthan11
Watertown 123
Wayland 17
Webster 173
Wellesley Fewerthan11
Wellesley Hills 16
Wellfleet 13
Wendell Fewerthan11
Wenham Fewerthan11
West Barnstable Fewerthan11
West Boylston 38
West Bridgewater 59
West Brookfield 24
West Chesterfield Fewerthan11
West Dennis 13
West Harwich Fewerthan11
West Hatfield Fewerthan11
West Newbury Fewerthan11
West Newton 46
West Roxbury 192
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City/town Hospital Dischargesxxiii(HPC analysis of CHIA data)
West Springfield 309
West Stockbridge Fewerthan11
West Tisbury Fewerthan11
West Townsend Fewerthan11
West Wareham 27
West Warren Fewerthan11
West Yarmouth 84
Westborough 80
Westfield 284
Westford 48
Westminster 18
Weston Fewerthan11
Westport 64
Westwood 52
Weymouth 174
Whately Fewerthan11
Whitinsville 95
Whitman 153
Wilbraham 65
Williamsburg Fewerthan11
Williamstown 17
Wilmington 176
Winchendon 63
Winchester 25
Windsor Fewerthan11
Winthrop 184
Woburn 305
Woods Hole Fewerthan11
Worcester 2,094
Worthington Fewerthan11
Wrentham 51
Yarmouth Port 27
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Appendix 5: Ratesofopioid-relatedhospitaldischargesingatewaycities
Under M.G.L. c. 23A section 3A, a Gateway City is defined as a municipality that has the following characteristics:
• Population between 35,000 and 250,000;
• Median household income below the state average; and
• Rate of educational attainment of a bachelor’s degree or above that is below the state average.64
Out of 26 gateway cities in Massachusetts, the 12 in which residents are utilizing the hospitals for opioid-related 
reasons are concentrated in just 4 areas of the state: (1) Central Massachusetts; (2) Southeastern Massachusetts; (3) 
Merrimack Valley; (4) Metro Boston; (5) Metro South; and (6) the South Shore. 
5.1: Total rate of opioid-related hospital discharges 
in Central Massachusetts
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges include both ED discharges and inpatient 
discharges.  
5.2: Total rate of opioid-related hospital discharges 
in Southeastern Massachusetts
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges include both ED discharges and inpatient 
discharges. 
5.3: Total rate of opioid-related hospital discharges 
intheMerrimackValley
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges include both ED discharges and inpatient 
discharges. 
5.4: Total rate of opioid-related hospital discharges 
in Metro Boston, Metro South, and the South Shore
Source: HPC Analysis—CHIA, Hospital Inpatient Discharge Database and 
EmergencyDepartmentDatabase,2014
Note: Hospital discharges include both ED discharges and inpatient 
discharges. 
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Appendix 6: Opioid-relatedhospitaldischarges,MassachusettsandCityofBoston,2014
Massachusetts’ hospitals treat large numbers of patients for opioid-related illnesses. Boston Medical Center (Boston), 
Good Samaritan Medical Center (Brockton), and Mercy Medical Center (Springfield) had the highest volume of 
opioid-related hospital discharges.
The City of Boston experiences a large volume of opioid-related hospital discharges in comparison to other cities 
in the Commonwealth. 
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Appendix 7: Valueofprovidershavingaccesstoprescriber-leveldata
Opioid prescription rates in Melrose-Wakefield and Lawrence Memorial Hospital EDs before and after access 
to practice pattern data. 
Source: Data provided by Hallmark Hospital System. Figure adapted from the Health Policy Commission Community Hospital Acceleration, 
Revitalization, and Transformation Program: Phase 1 – Foundational Investments for Transformation Report 
Baseline
Period of Performance
10%
20%
30%
40%
50%
Melrose-Wakeld HospitalLawrence Memorial Hospital
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